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ABSTRACT OF THE DISSERTATION 
AN INVESTIGATION INTO THE ADDUCT FORMING POTENTIAL OF DRUGS 
OF ABUSE WITH PEPTIDES AND PROTEINS  
by 
Richard Allen Gilliland 
Florida International University, 2018 
Miami, Florida 
Professor Anthony DeCaprio, Major Professor 
Hemoglobin and serum albumin, two prevalent proteins in human blood, 
contain unbound cysteine thiol moieties, creating a nucleophilic site with the 
potential for covalent modification by reactive chemical species.  These covalent 
modifications, called “adducts”, are stable entities that accumulate during acute 
and chronic exposure and remain covalently bound for the life-span of the 
protein.  Despite their current use as exposure markers for a variety of 
compounds, the use of adducts in assessing exposure to drugs of abuse has not 
yet been explored. The goal of this work was to examine the in vitro adduct 
forming capability of selected drugs of abuse with hemoglobin to provide 
additional proof of principle for the development of a real-world detection and 
monitoring analysis method.  This goal was accomplished by first analyzing the 
binding capabilities of the drugs of interest with glutathione, a smaller tripeptide. 
Use of protein adducts as biomarkers of drug exposure may allow for an 
increased window of detection, from several days to several months, as 
compared to current blood analysis methods.  In total, there were 16 drugs 
viii 
 
analyzed in the research, and they covered a wide range of abused drugs, 
including cocaine, methamphetamine, and Δ9-THC. 
 Results from the glutathione trials showed that 10 of the 16 the drugs of 
interest were able to form covalent adducts with the free thiol moiety, with four 
drugs forming more than one novel adduct. The MS results for hemoglobin 
showed 11 adducts formed for five of the drugs under investigation. Additional 
MS/MS confirmatory data was obtained for two of those 11 adducts. I 
successfully identifyied adducts formed between drugs of abuse and glutathione 
and hemoglobin, which have the potential to be used as long-term biomarkers of 
exposure. 
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1. INTRODUCTION 
 Xenobiotic drugs have been used by humans for millennia and continue to 
be a problem today. The current detection methods for drugs of abuse involve 
the identification of a biomarker of exposure in a bodily matrix; typically blood, 
urine, or hair. The biomarkers used for drug analysis are either the parent drug or 
a common metabolite which can be analyzed. For blood and urine analysis, 
drugs and metabolites are generally only observable for several days, with 
lipophilic drugs existing in the system for no more than two weeks. For hair 
analysis, the biomarkers may be detected several months, or possibly years, 
after ingestion, depending upon the length and rate of growth of the individual’s 
hair. Current hair analysis has many obstacles however, including a lack of 
consensus regarding incorporation of biomarkers into hair, wide variation of 
extraction methods, and the limited ability to distinguish between internal drug 
incorporation and external surface exposure. 
 A type of biomarker that has not yet been widely applied to the analysis of 
drugs of abuse involves measurement of covalent protein modifications (i.e., 
protein “adducts”). When xenobiotics are metabolized, some of the products 
created may be reactive metabolic species capable of forming covalent bonds 
with certain amino acid residues in proteins. Such protein adducts are, in 
general, much longer lived in the body than the parent compound or its 
metabolites.  
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The current research explored the capabilities of a wide variety of drugs of 
abuse to form covalent protein adducts with cysteine residues present in 
hemoglobin, a prominent and essential blood protein. This exploration was 
accomplished by first analyzing the adduct forming capabilities of the drugs with 
glutathione, a small tripeptide containing a reactive cysteine moiety, in an in vitro 
metabolic assay system. Following the characterization of the glutathione 
adducts formed, hemoglobin adducts were created and analyzed using the same 
in vitro assay, providing insight into the potential covalent adduct forming 
capabilities of the drugs of interest and the properties and localization of the 
generated protein modifications. My research establishes the potential for drug-
protein adducts to be used as biomarkers of exposure and creates the necessary 
foundation for future work to continue with these compounds toward the goal of a 
validated and widely applicable alternative to hair analysis for retrospective 
abused drug detection. 
2. LITERATURE REVIEW 
2.1 Drugs of Abuse  
 In 2014, there were an estimated 44 million drug users in the United 
States, with the numbers continually increasing.1 Despite their prevalence and 
popularity in today’s society, many plant-based produced drugs of abuse like 
heroin and cocaine have long and elaborate histories. Opium, from which heroin 
is derived, can be traced back over 1000 years to the ancient Greeks, whereas 
3 
 
cocaine was used for religious and ceremonial reasons by the ancient 
civilizations in the Americas.2,3 Over the years, the number of abused drugs has 
continued to increase and now includes many synthetic compounds in addition to 
the naturally derived ones.4 In the United States, the Drug Enforcement 
Administration (DEA) categorizes drugs into five schedules according to a drug’s 
medical uses and dependency potential.5 Any drug that does not fit into one of 
the DEA’s five schedules is categorized as an over the counter (OTC) medication 
or non-scheduled prescription medication. Table 1 lists all of the current DEA 
schedule classifications and the properties of the drugs found in each one.  
 
Schedule I 
Drugs, substances, or chemicals with no currently accepted 
medical use by the federal government and a high potential for 
abuse 
Schedule II 
Drugs, substances, or chemicals with high potential for abuse, 
but which do have an accepted medical use 
Schedule III 
Drugs, substances, or chemicals with moderate to low potential 
for abuse and dependence 
Schedule IV 
Drugs, substances, or chemicals with low potential for abuse 
and dependence  
Schedule V 
Drugs, substances, or chemicals with lower potential for abuse 
than Schedule IV and preparations containing limited quantities 
of certain narcotics 
 
Depending upon the source consulted, there are generally anywhere from 
four to eight recognized classes of abused drugs  upon pharmacological effect.6-9 
These classes include depressants, stimulants, hallucinogens, opioids, 
antipsychotics, cannabis, and novel psychoactive substances (NPS).10 These 
categories are a result of categorizing the drugs depending primarily upon the 
Table 1. Drug schedules as determined by the U.S. DEA. 
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effect on the central nervous system (CNS) of the user and the source of the 
compound itself. There will often be some overlap regarding the CNS effects of 
these classes.  For example, opioids have a similar effect to most depressants 
yet are categorized separately.  
The drugs of interest in this study included α-pyrrolidinopentiophenone, 
acetaminophen, alprazolam, buprenorphine, clozapine, cocaine, diazepam, 
methadone, methamphetamine, methylenedioxymethamphetamine, 
methylenedioxypyrovalerone, methylone, morphine, naltrexone, oxycodone, and 
Δ9-tetrahydrocannabinol. Table 2 shows the schedule and drug class for each of 
these compounds along with other identifying information. 
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Drug Name Abbreviation Formula Schedule Class 
α-Pyrrolidinopentiophenone α-PVP C15H21NO I 
NPS/ 
Stimulant 
Acetaminophen APAP C8H9NO2 OTC Analgesic 
Alprazolam ALP C17H13ClN4 IV Depressant 
Buprenorphine BUP C29H41NO4 III Opioid 
Clozapine CLZ C18H19ClN4 Rx Antipsychotic 
Cocaine COC C17H21NO4 II Stimulant 
Diazepam DZP C16H13ClN2O IV Depressant 
Methadone META C21H27NO II Opioid 
Methamphetamine METH C10H15N II Stimulant 
Methylenedioxymethamphetamine MDMA C11H15NO2 I 
Stimulant/ 
Hallucinogen 
Methylenedioxypyrovalerone MDPV C16H21NO3 I 
NPS/ 
Stimulant 
Methylone METY C11H13NO3 I 
NPS/ 
Stimulant 
Morphine MOR C17H19NO II Opioid 
Naltrexone NAL C20H23NO4 Rx Opioid 
Oxycodone OXY C18H21NO4 II Opioid 
Δ9-Tetrahydrocannabinol THC C21H30O2 I Cannabinoid 
 
Table 2. The drugs of interest selected for this study in addition to the abbreviations used 
for each. Table 2 also lists the formula, US DEA schedule, and general class of each drug 
of interest. 
2.2 Drug Metabolism 
 The lifespan of any xenobiotic within the body can be characterized by its 
absorption, distribution, metabolism, and excretion (ADME) parameters. 
Absorption describes the process by which a compound is taken up by the body, 
and the process is affected by the route of administration. Distribution refers to 
the overall pharmacokinetics of an absorbed chemical species, specifically the 
transfer of a chemical from where it was absorbed to where it may have an 
effect. Metabolism refers to the breakdown of a precursor chemical into its 
metabolites. These metabolites may be either pharmacologically active or 
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inactive. Excretion is the process of removing chemicals and their metabolites 
from the body; failure to efficiently removed compounds may lead to 
accumulation over time. As previously stated, the metabolism of a chemical 
species may result in pharmacologically active metabolites capable of producing 
unforeseen and toxic results. As a result of factors such as nutritional state, 
gender, and dosage, no two individuals will metabolize the same drug in the 
same way11, although it is possible to determine general metabolic trends for 
drugs and classes of drugs.  
2.2.1 Phase I Metabolism 
Metabolic processes may be divided into two categories: Phase I and 
Phase II metabolism. Phase I metabolic processes generally form metabolites 
which are more polar than the parent xenobiotic and are typically a means of 
detoxification (or, in some cases, toxification) and preparation for excretion.  
Phase I metabolism refers to a number of reactions that a xenobiotic may 
undergo where a relatively small chemical modification, such as a hydroxylation 
or an epoxidation, occurs which may slightly increase hydrophilicity.  While 
Phase I metabolic reactions occur in a variety of organs and tissues in the body, 
these reactions are predominantly carried out by cytochrome P450 (CYP) 
enzymes in the liver, with some estimates stating this organ accounts for ~90% 
of all metabolic activity.12  
 The CYP enzymes are a type of enzyme known as hemoproteins, thus 
named due to a heme group located in the active site of the protein. For more 
information regarding the heme complex, see 2.4.4. The heme group is 
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responsible for the CYP family’s activity as Phase I metabolic enzymes. CYP 
enzymes are capable of catalyzing otherwise difficult chemical oxidations, 
including hydroxylation of unfunctionalized alkyl chains13, which is accomplished 
via cycling the oxidation state of the iron within the heme group, as can be seen 
in Figure 1. This cycling process is proposed many times in the extant literature 
on CYP enzymes14-16. In step (a), the ferric iron of the CYP enzyme is hexa-
coordinated and in the low-spin state when the substrate to be oxidized (RH) is 
introduced, leading to the loss of a water molecule and the formation of a high-
spin penta-coordinated complex (b). Following the reduction of the iron to ferrous 
FeII (c), the iron can react with an oxygen molecule to form an oxygenated 
species (d), which is then further reduced to give a peroxy-complex (e). After the 
addition of two protons, heterolytic cleavage results in an oxo-ferryl oxenoid 
intermediate (f). A hydrogen atom is then abstracted from the substrate in 
solution, producing the reduced hydroxy ferric species and substrate radical (g). 
This production leads to a coordinated oxidized substrate species which then 
releases the oxidized substrate and produces the initial low-spin ferric compound 
(a). The CYP enzymes are not only responsible for hydroxylations, as they are 
capable of performing multiple other oxidative biotranformations on xenobiotics, 
as seen in Table 3.  
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Chemical 
group 
Reactions 
Alkane Hydroxylation, 
dehydrogenation 
Alkene Epoxidation 
Alkyne Oxidation to carboxylic acid 
Arene Hydroxylation, epoxidation 
Aniline N-hydroxylation 
Ester Oxidative cleavage 
Ether O-dealkylation 
 
  
 
Figure 1. The process of heme cycling by a CYP enzyme to produce an oxidized substrate. 
Table 3. Some of the chemical groups which may be metabolized by CYP enzymes and the 
reactions possible with each. 
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Another means of oxidation in a molecule is the process of an “NIH” shift, 
named for the National Institute of Health, where it was first described.17 There 
are several proposed mechanisms by which an NIH shift may occur, however, 
the prevailing theory, which has been experimentally corroborated, involves 
formation of an unstable epoxide which then undergoes a hydride shift.17,18 While 
the process is typically followed by a rearomatization step, in situations where 
GSH or a similar nucleophile is present, rearomatization is not always seen19.19 
2.2.2 Phase II Metabolism 
Phase II metabolism refers to reactions where the addition of a large polar 
moiety substantially increases hydrophilicity, such as conjugation to glucuronic 
acid.  The increase in hydrophilicity results in more facile excretion of the 
compound from the body in the urine. In contrast, conjugation with glutathione, 
particularly in the liver, can result in excretion of Phase II metabolites via bile and 
feces.  There are several metabolic processes which may result from Phase II 
metabolism, as can be seen in Table 4. Table 4 also shows some of the various 
enzymes and cofactors required for these reactions to take place. 
Process Enzyme Co-Factor 
Methylation methyltransferase S-andeosyl-L-
methionine (SAM) 
Sulfation Sulfotransferase 3’-phosphoadenosine-
5’-phosphosulfate 
(PAPS) 
Acetylation N-acetyltransferase Acetyl coenzyme A 
Glucuronidation UDP-glucuronosyltransferase UDP-glucuronic acid 
Glutathione 
conjugation 
Glutathione-s-transferase Glutathione 
 
Table 4. Phase II metabolic processes and the respective enzymes and co-factors required 
for each 
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2.3 Biomarkers of Exposure 
 Biomarkers of exposure are entities which are indicative of exposure to a 
chemical or class of chemicals. In terms of drugs of abuse, the most commonly 
analyzed biomarkers to determine exposure are either the parent drug or a stable 
metabolite. Since metabolism primarily occurs in the liver and metabolic 
processes are designed to facilitate excretion, biomarkers are selected on the 
basis of the specific matrix collected for analysis. Although there are many 
different matrices that may be utilized for the analysis of drugs, the three primary 
ones are blood, urine, and hair, with each offering benefits and drawbacks. 20-22 
2.3.1 Blood and Urine as a Matrix 
 Blood and urine are both well-characterized matrices with extensive 
protocols for exposure biomarker analysis established in the literature.22-25 While 
it may be possible to detect precursor drugs and their metabolites in both blood 
and urine, precursor drugs are typically used as biomarkers in blood and 
metabolites used as biomarkers in urine. Since blood and urine are both aqueous 
matrices, the utilization of liquid chromatographic (LC) separation in analysis 
requires fewer steps, as there are typically few solubility issues with the desired 
biomarker analytes. While a plethora of information already in the literature 
addresses many potential problems with the analysis of drugs in both blood and 
urine, they each still have drawbacks. Both blood and urine are collected via 
invasive means, leading to privacy issues in collection.26 Blood and urine also 
have limited windows of detection for currently utilized biomarkers. 27 Depending 
upon the properties of the drug, the window of detection may be less than a 
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day28, with some more lipophilic drug biomarkers being detectable for no more 
than about a few weeks. 29 A comparison of several drugs of abuse and their 
relative windows of detection in both blood and urine can be found in Table 5.28 
 
Parent Drug Analyte Detection Time in 
Blood (h) 
Detection 
Time in Urine 
(h) 
Methamphetamine Methamphetamine 48 87 ± 51 
MDMA MDMA 24 48 
Cannabis THC 5 N/A 
Cannabis THCCOOH 36 87 
Heroin Morphine 20 11-54 
 
Table 5. A summary of the retention times in blood and urine for methamphetamine, 
MDMA, cannabis, and heroin, as reported in hours. 
 
 
 
2.3.2 Hair as a Matrix 
 The use of hair as a matrix is another common approach to drug analysis 
and exposure assessment. The literature regarding hair analysis is not as 
encompassing as it is for either blood or urine, but there are still many protocols 
published for the analysis of drugs in hair. Hair is collected through less invasive 
means than both blood and urine, and the window of detection for hair analysis 
can be significantly longer, with the potential for drugs to persist in hair for 
months or years. 21 A comparison of detection windows for each matrix can be 
found in Figure 2. In addition to the extended window of detection, the use of hair 
as a matrix also allows for segmental analysis.  Segmental analysis consists of 
the partitioning of the hairs collected and analyzing each partition separately, 
allowing for a timeline of previous drug exposure to be compiled for an individual. 
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30 The biomarkers typically examined in hair analysis are both parent drugs and 
their metabolites.31 Unfortunately, there is no single incorporation mechanism for 
drugs into the hair, as direct incorporation into hair from blood, adsorption from 
sweat, and adsorption from smoke or powders are all potential routes of 
incorporation.32 Additionally, in the existing protocols, there is no way to 
distinguish biomarkers present from ingestion of a compound from biomarkers 
present from surface contamination of the hair without first utilizing extensive 
washing procedures to remove external contaminants.33 These washing 
procedures are not guaranteed to remove all of the external contaminants, as 
some drugs may bind more strongly to hair than others.34 In addition, washing 
procedures may also result in loss of drug that was incorporated from the blood.  
Lastly, since hair is a solid matrix, there are several steps required prior to 
analysis to extract and clean up the sample to analyzed.30 
 
Figure 2. The window of detection for cocaine and its metabolites in blood, urine, and hair 
set to a logarithmic scale.35 
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2.4 Use of Protein Adducts as Exposure Biomarkers 
The drawbacks in the use of blood, urine, or hair as testing matrices for 
drugs and other xenobiotics has led to interest in the use of alternative matrices 
or biomarkers to bypass these difficulties. One such example is the use of protein 
adducts as biomarkers of exposure. Protein adducts are formed as the result of a 
covalent modification to a protein by a directly reactive xenobiotic or a metabolite 
formed by the xenobiotic. Covalent protein adduction is common occurrence in 
the body, with many modifications being of relatively low molecular weight, for 
example reactive oxygen species (ROS)36,37 and reactive nitrogen species 
(RNS)38,39. Larger modifications are possible however, with examples such as 
glutathionylation and lipid peroxidation product adduction.40 While some protein 
modifications may be unstable in certain protein microenvironments, as is the 
case with compounds such as 4-hydroxy-2-nonenal 41, in general, covalent 
protein adduct formation is an irreversible phenomenon 42. Unlike DNA, 
essentially no cellular repair mechanisms exist for covalent protein 
modifications42, meaning that most protein adducts are typically extant for the 
remaining life of the protein.  
Recognition of the adduction of reactive electrophiles created in vivo to 
proteins first emerged in the 1930s and 1940s, first with Fieser’s work regarding 
the hepatotoxicity of various hydrocarbons43 and then with work done by Miller 
and Miller regarding the binding of aminoazo dyes to the cellular constituents of 
the livers of rats fed p-dimethylaminoazobenzene, a known hepatic carcinogen44. 
These studies laid the groundwork for what became known as the “covalent 
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binding theory”, which proposed that certain chemicals were able to covalently 
bind to macromolecules in the body causing toxicity.45 This progression 
continued when Brodie, et al. were able to show that bromobenzene is 
metabolically activated and covalently binds to proteins in the liver, resulting in 
liver necrosis.46 Since then, the concept of xenobiotic induced protein adduction 
has continued to expand and is now a major area of interest for new drug 
development where such adducts may mediate drug toxicity or participate in the 
therapeutic mechanism of certain drugs.45 
The use of protein adducts as exposure biomarkers is also not a new 
concept. Since the idea of utilizing them for the biomonitoring of various 
compounds was first suggested in the 1970s 46,47, research regarding protein 
adducts has continued to expand. In 1986, Skipper et al. looked at new analytical 
methods to measure protein adducts with 4-aminobiphenyl48, an arylamine 
capable of causing bladder cancer in human and dogs.49 Research published in 
1989 by Tornqvist et al. analyzed protein adducts formed upon exposure to four 
types of gasoline and diesel exhaust.50 In 1993, Christakopoulos et al. 
characterized styrene-protein adducts present in authentic collected blood 
samples from factory workers exposed to styrene.51    
2.4.1 Protein Adduction by Drugs of Abuse  
 With few exceptions, there are only limited data available regarding the 
potential for important drugs of abuse to form covalent adducts with blood or 
tissue proteins. One of the major exceptions is ethanol, where its ability to 
interact with proteins has been widely studied. Ethanol’s major metabolite, 
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acetaldehyde, is known to form adducts with proteins. The reaction between 
acetaldehyde and serum albumin was first characterized in 198252, and the 
reaction with hemoglobin was first characterized in 198553. Acetaldehyde’s 
protein interactions are generally the result of the formation of an unstable Schiff 
base, which then is able to interact with nucleophilic amino acids of proteins.54 
These bases may form stable or unstable adducts, and the stable adducts may 
be useful as a means of retrospective detection of exposure.55,56 
 Some data are also available for protein adduction by the licit drug 
morphine, which is both itself abused and that is a major metabolite of the illicit 
drug heroin. A major reactive metabolite of morphine, morphinone, has been 
shown, in both in vitro and in vivo studies, to covalently bind to free thiols of 
proteins and peptides found in the body.56-59 In vitro studies by Correia, et al. 
suggested that formation of a more reactive and unstable reactive species is the 
preferred biological transformation of morphine, as the glutathione-morphine 
adduct formed by this reactive intermediate was observed at levels two-fold 
greater than those of normorphine.60 Previous work Schneider and DeCaprio 
also demonstrated the ability of morphine metabolites to form adducts with N-
acetylcysteine, glutathione, and a synthetic hexapeptide.56  
Another example of an illicit drug which has shown the capability of 
binding to protein is cocaine.61 The major site of metabolic activity for cocaine is 
reported to be the tropane nitrogen, with numerous oxidative products capable of 
being formed at this site.62 Cocaine adducts formed with liver proteins have been 
observed in several studies, with further studies into potential hepatotoxic stress 
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caused by these adducts.63,64 In 2002, Deng, et al. reported high levels of 
covalent binding between metabolically activated cocaine and blood proteins.65 
Additional work by Schneider and DeCaprio investigated the binding of cocaine 
to glutathione, a synthetic hexapeptide, and N-acetylated variants of the amino 
acids lysine (Lys), cysteine (Cys), and histidine (His).61 Schneider and DeCaprio 
also posited that epoxidation of the phenyl ring of cocaine is the first step in the 
formation of cocaine adducts, suggesting that the phenyl ring is the site of 
adduction.61 This reaction scheme contrasts with what was reported in the 1980s 
and 1990s that the tropane nitrogen was the likely site of adduction.66,67 
2.4.2 Hard-Soft Acid-Base Theory 
 The formation of covalent adducts from the reaction of electrophilic 
xenobiotics with cellular nucleophiles, including proteins, can be generally 
modeled by the “Hard and Soft Acids and Bases” (HSAB) Theory. The HSAB 
Theory states that nucleophiles and electrophiles can be categorized on a 
spectrum from hard to soft, depending on polarizability. Polarizability is a 
characteristic describing electron density for atoms or molecules, and it applies to 
the valence electrons in an atomic or molecular electron cloud.68 If the valence 
electrons in the cloud are occupying a large volume of space, they will be more 
susceptible to outside influence and thus be more polarizable than valence 
electrons which are closer to the nucleus and relatively less mobile. These 
electrons are considered more polarizing.69 Using this nomenclature, “hard” 
refers to a nucleophile or electrophile that is relatively small and highly polarizing. 
Alternatively, “soft” refers to a nucleophile or electrophile that is relatively large 
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and highly polarizable. According to HSAB Theory, hard electrophiles will tend to 
react with hard nucleophiles and vice versa for soft electrophiles and 
nucleophiles. 
 A species’ hardness or softness cannot be directly measured, but instead 
can be calculated via its relation to other properties of the compound. The energy 
levels of the outermost or frontier molecular orbitals (FMOs) are the most 
important component in determining a compounds “hardness”.61 A species’ 
hardness (η) is equal to the energy of the Lowest Unoccupied Molecular Orbital 
(LUMO) minus the energy of the Highest Occupied Molecular Orbital (HOMO) 
divided by 2 (Equation 1). A species’ softness (σ) is then defined as the inverse 
of the hardness (Equation 2).  
(1) 𝜂 =
𝐸𝐿𝑈𝑀𝑂−𝐸𝐻𝑂𝑀𝑂
2
 
(2) 𝜎 =
1
𝜂
 
When dealing with electrophilic species, it is generally the case that a higher 
softness results in more facile formation of an adduct with a soft nucleophile.68 
The electrophilic index (ω) is a parameter that combines softness and electric 
potential (μ), or the propensity for a compound to undergo a chemical change 
(Equations 3 and 4). 
(3) 𝜇 =
𝐸𝐿𝑈𝑀𝑂+𝐸𝐻𝑂𝑀𝑂
2
 
(4) 𝜔 =
𝜇2
2𝜂
 
The equations presented thus far only apply to an individual species and do not 
provide insight into bond forming capabilities between two compounds. For this, 
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the nucleophilic index (ω-) can be calculated to predict the likelihood that an 
adduct will form between nucleophile A and electrophile B (Equation 5).70 
(5) 𝜔− =
𝜂𝐴(𝜇𝐴−𝜇𝐵)
2
2(𝜂𝐴+𝜂𝐵)2
 
 When dealing with biological species, heteroatoms such as sulfur, oxygen, 
and nitrogen are the most prominent nucleophilic sites.71 Specifically when 
dealing with proteins, the sulfurs from amino acid thiol residues react as relatively 
soft nucleophiles.72 The softness of the thiol moiety increases as it is converted 
to a thiolate (SH  S-) ion, and the thiolate ion is one of the most reactive 
biological nucleophiles.68 The base pKa of cysteine is ~8.3, meaning that at 
physiological pH (~7.4) most of the cysteine residues present should be 
unionized and not in the more reactive thiolate form73 However, the formation of 
the thiolate ion by cysteine residues may be promoted by the three-dimensional 
interactions between cysteine and any surrounding basic amino acid residues.74 
Because of the softness of these thiol residues, cysteines have become a major 
site of interest in regards to formed protein adduct investigations.  
 Two key components of new drug discovery and development are HSAB 
interactions and the potential for drug-protein adduct formation.75 Concern for 
lack of protein-binding specificity and potential for unknown side effects has led 
pharmaceutical companies to avoid drugs that show the capability for covalent 
protein binding.76 Despite this, Robertson found in 2005 that 25 of 71 biological 
targets examined were covalently bound by marketed drugs.77 Since so many 
compounds are capable of these drug-protein interactions, some researchers 
have begun exploring what are termed covalent inhibitors, or drugs which 
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covalently bind to a protein causing inhibition.78 Whether protein adduction is the  
desired outcome or a negative side effect, HSAB theory is key in the preliminary 
steps of drugs development and discovery. 
2.4.3 Glutathione 
 One prominently reactive biological thiol can be found as part of glutathione 
(GSH), an endogenous tripeptide which plays an important role in the removal of 
reactive oxygen species (ROSs) in the body. The structure of GSH consists of 
glutamic acid, cysteine, and glycine, with a γ-peptide linkage between glutamic 
acid and cysteine (See Figure 3). Endogenous concentrations of GSH in human 
cells range up to 10 mM, with higher concentrations occurring in the liver.79 The 
free thiol moiety of GSH acts as a reactive nucleophilic site, and it has been 
shown to covalently bind to electrophiles in vivo.80,81 The capability of GSH to 
bind to reactive metabolites allows it to function as one of the primary cellular 
defenses against electrophilic/oxidative stress and damage.  Because of GSH’s 
reactivity and prevalence in the body, GSH adducts have also been used as 
markers to identify, analyze, and monitor exposure to and excretion of 
compounds of interest.58,82-84 The chemistry and structure of GSH make it an 
ideal candidate for a trapping agent when utilized in an in vitro metabolic 
assay.85-87 
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Figure 3. The chemical structure of glutathione showing the appropriate charges on the 
terminal carboxy groups and the amine group. 
 
 Modification of GSH by both licit and illicit drugs has been well-studied and 
reported in the literature.56,61,84,88-92 The first recorded observance of a GSH 
adduct with acetaminophen was reported by Dahlin et al. in 1984. They reported 
that N-acetyl-p-benzoquinone imine (NAPQI), a reactive metabolite of 
acetaminophen, was reduced and formed a covalent conjugate with the GSH, 
although they could not confirm the presence of NAPQI in the assay.80 Work in 
1988 by the National Institute of Environmental Health Sciences explored the 
HPLC-MS analysis of GSH conjugates formed with compounds such as 
acetaminophen and 3-methylindole.93 Fragmentation characterization of a GSH 
adduct formed with a derivative of acetaminophen was performed in 1993 by 
Ballie and Davis.94 Furthermore, a wide variety of licit drugs, such as troglitazone, 
dantrolene and raloxifene90; nefazodone92; and clozapine, naproxen, and 
ibuprofen88, have all been analyzed as GSH adducts. 
 Although not as widely studied as licit compounds or endogenous ROSs, 
GSH adducts with common illicit drugs of abuse have been reported throughout 
the literature. One predominant example is 3,4-
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methylenediaminemethamphetamine (MDMA). Ramaley et al., who explored the 
in vitro metabolism of MDMA with GSH present in the assay, observed two 
possible GSH adducts; one formed with MDMA and the other with the oxidized 
catechol of MDMA, 3,4-dihydroxymethamphetamine.95 Meyer et al. further 
explored the adduct forming capabilities of 15 methylenedioxy designer drugs, 
including both MDMA and methylenediaminepyrovalerone (MDPV), and 
characterized the major fragments for the observed adducts.84 They were able to 
successfully identify common fragmentation patterns which applied to 
methylenedioxy designer drugs and their major metabolites. As previously 
mentioned, work performed by Schneider and DeCaprio characterized the 
covalent conjugates formed by GSH and the drugs morphine, cocaine, and 
methamphetamine, and delved into the kinetics and electronics involved in the 
formation of the observed adducts.56 Morphine is another commonly abused drug 
which has a GSH adduct which has been observed. In 2005, Todaka et al. 
reported a GSH adduct with morphinone, the major metabolite of morphine, for 
the first time.58 
2.4.4 Hemoglobin as a Target for Reactive Xenobiotics 
Hemoglobin (Hb) is a protein found in high concentrations in erythrocytes (red 
blood cells). The protein is used for the transport of oxygen and carbon dioxide 
throughout the body. In adults, erythrocytes are produced in the bone marrow 
through a process called erythropoiesis. Erythrocytes have a biconcave 
symmetrical structure and contain no nucleus. Hemoglobin derives its name from 
the two heme groups contained within its four globin protein subunits. Heme is an 
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iron coordination complex, where the central iron atom is coordinated to the four 
nitrogen atoms of a porphyrin ring system. The specific heme found in 
hemoglobin is Heme B (Figure 4). 
 
Figure 4. The porphyrin ring system found in the heme B iron complex of hemoglobin.  
 
 
There are six potential subunits of the Hb protein, however at least 95% of the 
Hb found in an adult human is made up of the two subunits alpha and beta.96 The 
amino acid sequences of the alpha subunit (Hbα) of Hb was first reported in 
196297, with the beta subunit (Hbβ) sequence being published just one year later 
in 196398. There are only three cysteine residues contained in Hb, Hb α104Cys, 
Hb β93Cys, and Hb β112Cys. Of these residues, Hb β93Cys has been shown to be 
the most susceptible to adduction by soft electrophiles, followed by Hb β112Cys 
23 
 
and Hb α104Cys , respectively.99 The lifespan of erythrocytes in human blood, and 
thus of Hb, is approximately 120 days, implying that the maximum lifespan for an 
adduct at any of these three cysteines would be 120 days.100 
A key issue when utilizing hemoglobin adducts as exposure biomarkers is the 
capability of xenobiotics to enter into the erythrocyte to interact with the 
hemoglobin molecule. Erythrocytes generally travel through body about once 
every minute, totaling about 250km throughout the lifespan of a single cell101, 
meaning that there is ample opportunity for xenobiotics and their metabolites to 
interact with the cells. While hemoglobin is contained within the cellular 
membrane of the erythrocyte, studies have shown that many compounds are 
capable of passing through this membrane to potentially reach the protein.101 
There are several examples in the literature regarding uptake of chemicals by 
erythrocytes, including cyclosporine A102, the carbonic anhydrase inhibitor MK-
927103, and chloroquine104. Although other factors, such as temperature and pH, 
have been shown to play a role in the uptake of certain compounds by 
erythrocytes105, the above mentioned species are all partitioned via passive 
diffusion through the cellular membrane.101 
 Hemoglobin adducts have been utilized as biomarkers of exposure to 
xenobiotics in the past. The compounds which have been studied up to this point 
have primarily been focused on environmental exposure to toxic chemicals. In 
vivo experiments in the early 1990s used rats exposed to over 40 arylamines, 
including several pesticides, to analyze the adducts formed with 
hemoglobin.106,107 These studies noted the potential for the use of hemoglobin 
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adducts as a biomarker of exposure to toxic pesticides. The focus on arylamine 
toxicity and adduct formation continued in 1996, when McClure et al. described 
hemoglobin adducts formed with the herbicides propanil and fluometuron and 
proposed a mechanism of adduction for these compounds.108 Another application 
of hemoglobin adduct biomarkers is the exposure to chemical warfare agents, in 
particular sulfur and nitrogen mustard gases. Sulfur and nitrogen mustards have 
both been shown to bind covalently to hemoglobin at multiple nucleophilic 
residues, including cysteine and terminal valine residues and to a lesser extent 
histidine and lysine residues.73,109 
2.5 LC-MS Analysis of Covalent Protein Modifications 
Since peptides and proteins are non-volatile compounds and extracted 
solutions of such compounds from biological matrices will contain hundreds to 
thousands of components with varying masses, the mass spectrometric analysis 
of such species generally requires LC separation prior to analysis. The LC 
separation requires a liquid solution containing the analytes be passed through a 
column packed with a sorbent material. As the solution passes through the 
column, the analytes interact with the sorbent material, and the strength of these 
interactions affects how quickly the analytes pass through the column. Thus, LC 
is a means to separate compounds via overall retention times within the column. 
Following LC separation, mass spectrometry (MS) is used to analyze the 
compounds as they are eluted from the column. Mass spectrometry is the  
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analysis of chemicals by a mass-to-charge ratio (m/z). Using the m/z, the 
projected mass of a chemical species can be predicted.  
Mass spectrometers can also provide information about the overall 
structure of a compound using fragmentation produced by collision induced 
dissociation (CID). The fragmentation resulting from CID is caused by high speed 
collisions occurring between a neutral gas molecule and a chemical analyte in 
the gaseous phase. When the molecules collide, kinetic energy from the neutral 
gas is transferred to the analyte resulting in bond breakage. Fragmentation 
patterns may be specific to certain functional groups or structural components. 
The process of data collection for the precursor analyte and the fragments 
produced by CID is referred to as tandem mass spectrometry, or MS/MS 
analysis. 
Two common mass analyzers for MS/MS are the triple quadrupole (QqQ) 
and the quadrupole time-of-flight (QTOF). A QqQ MS, as the name suggests, 
consists of three quadrupoles in series. The first of these quadrupoles (Q1), is 
used to select which ions are allowed to pass through the instrument. The 
second quadrupole (q or Q2), is used as a collision cell for CID to produce 
characteristic fragments.  The third quadrupole (Q3), is used to select which 
specific fragments produced in the collision cell will pass through to the detector. 
There are several scanning modes possible with a QqQ depending upon which 
m/z ratios are selected, including as product ion scans, precursor ion scans 
(PIS), neutral loss scans (NLS), and selected reaction monitoring or multiple 
reaction monitoring (MRM) (Figure 5). 
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Figure 5. This diagram shows the four major scanning modes for an LC-QqQ-MS system. 
 
Of particular interest in the present research is the PIS, as certain 
peptides such as GSH have specific fragmentation patterns which are indicative 
of GSH adducts.110 Negative mode analysis of GSH-containing compounds 
provides very characteristic fragments at m/z 306, 272, 254, 210, 179, 160, 143, 
and 128, with more fragments possible depending upon the ionized molecule 
mass, or [M+H]+, of the compound.88,110 For example, [M+H]+ - 273 refers to an 
indicative fragment where the precursor adduct is missing a portion with a m/z of 
273. These specific fragmentation patterns of some peptides, in particular GSH, 
allows for more facile examination of these species than when utilizing positive 
ionization. 
The QTOF mass analyzer consists of an initial quadrupole for ion 
selection in tandem with a time-of-flight (TOF) chamber. All ions that pass 
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through the collision cell enter the chamber are given the same kinetic energy in 
a single direction by the orthogonal accelerator. The ions then all interact with the 
reflectron, which forces the ions back to the detector (Figure 6). This particular 
means of compound separation allows for high mass resolution and mass 
accuracy, which is helpful when analyzing complex peptide mixtures and is 
necessary for protein analysis.111,112
 
Figure 6. Schematic for a generic QTOF instrument, showing the quadrupole for ion 
selection (Q1), the collision cell (q2), orthogonal accelerator, reflectron, and detector.112 
The gas used in the collision cell for this research was N2. 
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2.6 Bottom-Up Proteomics 
 The MS analysis of proteins such as Hb is generally divided into three 
categories: top-down proteomics, middle-down proteomics, and bottom-up 
proteomics (Figure 7). Top-down proteomics refers the analysis of proteins by 
introducing a whole protein into the mass spectrometer and then fragmenting the 
protein into peptides via CID. The peptides are then analyzed to determine the 
overall structure and sequence, thus identifying the protein and its modifications. 
Middle-down proteomics utilizes a proteolytic digestion to break down the protein 
into mid-range molecular mass peptides before introduction into the mass 
spectrometer. The use of tandem mass spectrometry (MS/MS) allows for 
fragmentation of the enzymatically-produced peptides, and these data can 
provide insight into the amino acid chains which makes up the peptides. Bottom-
up proteomics is very similar to middle-down proteomics, except that it uses a 
proteolytic enzyme to break the protein into much smaller peptide chains. These 
are more useful than the mid-range peptides when the protein being analyzed is 
well-characterized and the sequence is already known. 
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Figure 7. This diagram shows the general procedures for top-down, middle-down, and 
bottom-up proteomics.113  
 
 When a proteolytic enzyme with a well-characterized cleavage pattern, 
such as trypsin, is used for the protein digestion prior to analysis in bottom-up 
proteomics, the resulting peptides can be analyzed with a high degree of 
accuracy. Trypsin is an enzyme that cleaves peptides at the carboxylic end of 
both lysine and arginine residues, except when followed by proline, with very 
high specificity.114 This specificity implies that a protein with a known amino acid 
sequence, such as Hb, will have a very predictable and reproducible collection of 
peptides produced by a trypsin digestion.  Trypsin also produces a very 
manageable average peptide length of approximately 14 residues114, suggesting 
that many of the produced peptides would be in a mass range most suitable for 
bottom-up proteomics. For example, the tryptic hemoglobin peptide containing 
Hb β93Cys is GTFATLSELHCDK, containing just 13 amino acids. 
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2.6.1 LC-MS Peptide and Protein Analysis 
Peptides fragment in specific patterns following CID. These fragmentation 
patterns are well-documented in the literature and are relatively straight-forward 
with few exceptions.112 The fragmentation along the peptide backbone can be 
used to determine amino acid sequences and alterations (adduction) to the 
specific amino acids of a known sequence. As can be seen in Figure 8, the 
fragments are given the nomenclature of a,b,c (if the charged is maintained on 
the N-terminus) or x,y,z (if the charge is maintained on the C-terminus), 
depending upon the cleavage of the  peptide bond. Of these formed fragments, 
the most commonly observed are the “y” and “b” fragments, or the fragments 
formed by the cleavage of the peptic bond between the carbonyl group and the 
amine.   
 
Figure 8. Peptide fragmentation patterns labeled with the common “a,b,c” and “x,y,z” 
nomenclature.  
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2.7 In Vitro Metabolic Assays 
The formation of drug metabolites in an in vitro system may be monitored 
by a metabolic assay system.  Such metabolic assays mimic the natural 
metabolism processes a xenobiotic may undergo in the human body.45 In vitro 
metabolic assays are typically used in pharmaceutical development to 
characterize stable and reactive drug metabolites formed by natural metabolic 
processes found in the human body.45,115 The most common types of in vitro 
metabolic assays utilize homogenized liver fractions containing various enzymes 
responsible for metabolism. These fractions include the S9 fraction, cytosol, and 
human liver microsomes (HLM).  The S9 fraction is the supernatant produced 
from initial low speed centrifugation of a liver homogenate.  When the S9 fraction 
is then centrifuged at higher speed (100 x g), the supernatant consists of the 
cytosolic fraction while the pellet consists of “microsomes” derived from rough 
endoplasmic reticulum.. Human liver microsomes (HLM), the metabolic system 
utilized in this research, contains a high concentration of the CYP enzymes 
responsible for Phase I metabolism described in section 2.2.1. 
2.7.1 In Vitro Metabolic Trapping Assays 
 As described previously, when certain xenobiotics are metabolized, 
reactive intermediates may also be formed, which may then modify nearby 
macromolecules to form covalent adducts, primarily through electrophilic-
nucleophilic interactions.116,117 The formation of these modifications can create a 
potential for organ-specific toxicity118,119 or, alternatively, can be innocuous.  In 
either case, such adducts may also serve as biomarkers of exposure.88 Metabolic 
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trapping assays have been widely employed to study these possibly harmful 
products in vitro, particularly in pharmaceutical development where there is a 
need to identify the potential for reactive metabolite production in candidate 
drugs.89,120 Such assays are designed to mimic Phase I and II metabolic 
processes in human cells.45 When a metabolic assay is used for the purpose of 
examining reactive metabolite formation, a trapping agent must be added as a 
target for covalent modification.121 Trapping agents are typically any one of 
numerous, primarily nucleophilic and generally small, molecules that can bind 
covalently to reactive intermediates, preventing further metabolism and 
preserving the structure of the otherwise unstable compound.61 Examples of 
trapping agents used in these assays include glutathione (GSH)89,122, N-
acetylcysteine61, and cyanide45, with the emphasis of this research being placed 
on GSH. Additionally, larger trapping agents may be used, such as larger 
peptides or whole proteins containing at least one nucleophilic site. 
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2.8 Research Objectives 
This research was performed to test three hypotheses: 
1. In vitro metabolic assays can successfully mimic in vivo metabolic 
processes for relevant drugs of abuse. 
2. Small peptides used as trapping agents in in vitro metabolic assays can 
form covalent adducts with reactive metabolites of drugs of abuse. 
3. These same adducted moieties can also be observed on whole proteins. 
The primary objective of this research was to observe and characterize covalent 
adducts with hemoglobin by reactive metabolites of certain drugs of abuse. This 
objective was accomplished by completing the following three tasks. 
1. Create and optimize a LC-MS/MS method for the detection and 
characterization of drugs of interest and stable drug metabolites. 
Specifically: 
a. Create a LC-MS method to determine the retention time of the 
parent drugs. 
b. Using retention times, create a targeted MS/MS method to 
determine and analyze common transitions for each parent drug. 
c. Perform metabolic assays and identify and confirm metabolites 
formed under assay conditions via LC-MS/MS. 
2. Create and optimize a LC-MS/MS method for the detection and 
characterization of reactive drug metabolites. Specifically: 
a. Optimize a metabolic trapping assay using glutathione as a 
nucleophilic trapping agent. 
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b. Analyze MS and MS/MS data collected from GSH studies to 
compile a list of possible adducts formed. 
c. Determine plausible structures for observed adducts using MS and 
MS/MS data. 
3. Confirm adduction in purified proteins by drugs of interest. 
a. Optimize a metabolic trapping assay to incorporate hemoglobin as 
a trapping agent. 
b. Analyze Hb trapping assays to determine sites of adduction and 
number of expected adducts. 
c. Confirm adduction with Hb by collecting MS/MS data for the Hb 
tryptic peptides.  
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3. Methodology 
3.1 Instrumentation 
Analysis by LC-QqQ-MS was performed on an Agilent 1290 Infinity ultra-
high performance liquid chromatography (UHPLC) coupled to an Agilent 6460 
QqQ MS.  Analysis by LC-QTOF-MS was performed on an Agilent 1290 Infinity 
UHPLC coupled to an Agilent 6530 QTOF MS. Both positive and negative ion 
scanning modes were used with the LC-QTOF-MS, while only negative mode 
ionization was used for the LC-QqQ-MS. Both instruments utilized Agilent Jet 
Stream electrospray ionization (ESI).  The column utilized for both instruments 
was an Agilent Zorbax Eclipse Plus C18 rapid resolution HD. Elution solvents, 
injection volumes, and LC pump parameters varied for experiments and are 
discussed below. Elution solvent flow rate was 0.3 mL/min. for all runs. Data 
acquisition for the QqQ and QTOF was performed using Agilent’s MassHunter 
Acquisition software (version B.06.00 for both systems). Data analysis was 
performed using Agilent’s MassHunter Qualitative software (version B.07.00), 
with supplementation by Agilent’s BioConfirm software (version B.08.00). 
3.2 Drug Selection 
 The drugs of interest in this study were selected based on a known 
potential for addiction/dependence and prevalent usage, while also ensuring that 
various structural and pharmacological classes of drugs were represented in the 
final list.  All of the selected drugs are examples of compounds which may be 
identified in authentic specimens from law enforcement cases, rehabilitation 
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centers, correctional facilities, and outpatient therapy. As mentioned in section 
2.1, the drugs of interest selected for this study were α-pyrrolidinopentiophenone, 
acetaminophen, alprazolam, buprenorphine, clozapine, cocaine, diazepam, 
methadone, methamphetamine, methylenedioxymethamphetamine, 
methylenedioxypyrovalerone, methylone, morphine, naltrexone, oxycodone, and 
Δ9-tetrahydrocannabinol. The two positive control compounds selected for this 
study are acetaminophen and clozapine, both of which have shown the capability 
of binding to endogenous nucleophiles. Radiolabeled acetaminophen has been 
shown to bind to the free cysteine in bovine serum albumin, with the adduct 
being identified as 3-cystein-S-yl-4-hydroxyaniline.123 Additional studies by 
James, et al. investigated the potential for liver induced toxicity by 
acetaminophen-protein adducts.124 McGill, et al. reported that acetaminophen-
protein binding is possible at subtoxic levels of administration and before levels 
of glutathione, a generally more favorable target of electrophilic compounds, 
were depleted.125 Both acetaminophen and clozapine have been shown to exhibit 
affinities to covalently bind to glutathione on multiple occasions.110,126-128 
3.3 Parent Drug Analysis 
 In order to determine the appropriate instrumental parameters for the 
analysis of the metabolites formed by the drugs of abuse, the parent drugs were 
analyzed for retention time and major fragments formed. Analysis of the parent 
drugs was performed using LC-QTOF-MS using positive ionization and full scan 
mode. Elution solvents for the parent drug analysis were A: 5 millimolar (mM) 
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ammonium formate in water with 0.1% formic acid and B: acetonitrile with 0.1% 
formic acid. Pump parameters were as follows: 0-2 min. 5% B, 2-5 min. ramp 
from 5% B to 50% B, 5-7 min ramp from 50% B to 100% B, hold at 100% B until 
10 min., followed by a two min. post-run for re-equilibration of the instrument to 
the starting configuration. A one part per million (ppm) solution in methanol was 
created for each of the 16 drugs used in this study (Table 2), except for APAP, 
which due to solubility issues was dissolved in water, and THC which was 
dissolved in ethanol. A 5 µL aliquot of each drug-containing solution was injected 
into the mass spectrometer, and the corresponding retention time was collected.  
Once retention times were collected for all parent drugs, mixtures were 
created containing three of the parent drugs with differing retention times. 
Targeted scan mode MS/MS analysis was performed on these five mixtures to 
collect major transitions using the same LC-MS parameters as the retention time 
collection. Transitions were collected at 10, 20, and 40 electron volts (eV) to 
ensure that complete fragmentation was achieved for all drugs. These scans 
were performed in triplicate, and the three consistently most prominent fragments 
were recorded.  
3.4 Drugs of Abuse Stable Metabolites 
3.4.1 Stable Metabolite Formation 
 Stable metabolites were analyzed for clozapine, which has prominently 
formed and well-established stable metabolites.129 These metabolites were 
studied to aid in the optimization of parameters for the in vitro metabolic assay 
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required for later research. Briefly, the stable metabolite assay consisted of final 
concentrations of 100 µM drug of interest, 1 mg/mL HLM, 2 mM nicotinamide 
adenine dinucleotide phosphate (NADPH), 3 mM magnesium chloride (MgCl2), 3 
mM glucose-6-phosphate (G6P), and 0.4 U/mL glucose-6-phosphate 
dehydrogenase (G6PD) with a total assay volume of 125 µL in 50 mM sodium 
phosphate buffer pH=7.4.  A high drug concentration and the use of an activating 
cofactor regeneration system were employed to ensure maximum formation of 
metabolites.  The assay components were combined in a microfuge tube and 
briefly vortexed to ensure uniformity.  The vials were then incubated at 37°C for 
two hours.  Following incubation, enzymatic activity was ceased by the addition 
of 25 µL ice-cold acetonitrile (6% acetic acid).  The vials were then centrifuged at 
15,000 x g at 4°C for 30 minutes.  After centrifugation, a 100 µL aliquot was 
removed and placed into a clean LC-MS vial for analysis.  
3.4.2 Stable Metabolite Analysis 
Stable metabolite analysis was performed using LC-QTOF-MS using 
positive ionization and full scan mode. Elution solvents for the parent drug 
analysis were A: 5 millimolar (mM) ammonium formate in water with 0.1% formic 
acid and B: acetonitrile with 0.1% formic acid. Injection volume was set to 1 µL. 
Pump parameters were as follows: 0-2 min. 5% B, 2-5 min. ramp from 5% B to 
50% B, 5-7 min ramp from 50% B to 100% B, hold at 100% B until 10 min., 
followed by a two min. post-run for re-equilibration of the instrument to the 
starting configuration. Collected spectra were compared to negative controls 
without a metabolic system, and the new peaks were analyzed. 
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3.5 Metabolic Trapping Assay with Glutathione 
 Once the in vitro assay parameters were optimized, adduction by reactive 
metabolites with GSH was studied. This process required a similar in vitro assay 
as the stable metabolites, but with the addition of a trapping agent. Briefly, 
components of the in vitro trapping assay were combined in a total assay volume 
of 125 µL of 50 mM sodium phosphate buffer, pH 7.4, at the following final 
concentrations: 1000 µM drug of interest, 1 mg/mL HLM, 3 mM MgCl2, 2 mM 
NADPH, 3 mM G6P, 0.4 U/mL G6PD, and 2 mM GSH.  Drug of interest is added 
to a clean microfuge tube and solvent is removed via vacufuge. Assay 
components without GSH were then combined in the microfuge vial and vortexed 
briefly to ensure uniformity, followed by a pre-incubation of 15 min at 37°C. The 
GSH was then added to complete the assay and achieve final assay volume, and 
vials were once again vortexed to ensure proper mixing. Incubation then ensued 
at 37°C for 3 h.  Upon completion of incubation, vials were immediately 
centrifuged at 15,000 × g at 4°C for 30 min.  Following centrifugation, 100 µL 
aliquots of supernatant were removed from each vial and placed in separate, 
clean LC vials. This assay method is illustrated in Figure 9. 
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Figure 9. Illustration of the metabolic trapping assay method utilizing GSH as a trapping 
agent. 
 
3.5.1 Glutathione Adduct Analysis 
 Preliminary analysis of GSH adducts was performed using positive 
ionization and full scan mode on the LC-QTOF-MS. Elution solvents for the 
parent drug analysis were A: 5 millimolar (mM) ammonium formate in water with 
0.1% formic acid and B: acetonitrile with 0.1% formic acid. Injection volume was 
set to 1 µL. Pump parameters were as follows: 0-2 min. 5% B, 2-5 min. ramp 
from 5% B to 50% B, 5-7 min ramp from 50% B to 100% B, hold at 100% B until 
10 min., followed by a two min. post-run for re-equilibration of the instrument to 
the starting configuration.  
 Negative mode analysis work began with the LC-QQQ-MS and used PIS. 
Elution solvents for GSH adduct analysis in negative mode were A: water with 
0.1% acetic acid, and B: 95% acetonitrile, 4.9% water, and 0.1% acetic acid.  
The pump timetable was as follows: 5% B hold for 1 min, 5% to 100% B ramp 
from 1 to 14 min, 100% B hold for 2 min, followed by a 3-min post-time for 
reequilibration to initial conditions for next injection. The precursor ion scan was 
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set to identify the precursor ions for any fragments with m/z 272, a common and 
indicative product of GSH, corresponding to GSH less the sulfur atom.110  The 
scan took place over the mass range m/z 400-800 to avoid interference from 
unreacted GSH ([M-H]- m/z 306) and to maximize detection of likely adducts for 
all drugs.  Peaks were determined to be potentially significant if they had an 
unscaled abundance higher than 1000 counts.  All peaks determined to be 
potentially significant for each drug had their m/z recorded.  The extracted ion 
chromatogram (XIC) MS spectrum was also collected for each potentially 
significant peak.  The XIC was examined for characteristic fragmentation 
common to GSH-containing compounds. 
3.5.2 Glutathione Adduct Confirmation 
 Negative mode analysis was continued on the LC-QTOF-MS. Initial analyses 
by QTOF-MS were performed using full scan mode.  In full scan mode, the mass 
range was again restricted to m/z 400-800 with fragmentor voltage set to 120 V 
and no collision induced dissociation.  Data were collected for this mass range 
over the entire run time and any prominent peaks of interest were recorded and 
then analyzed using targeted MS/MS.  In targeted mode, MS/MS data were 
collected only for the molecular ion peaks of interest, with the mass range set to 
m/z 100-800 to allow for smaller identifying fragments to be recorded at collision 
energies of 10, 20, and 40 eV to allow for full visualization of fragments formed. 
Compounds with fragmentation consistent with masses commonly seen for 
fragmentation of GSH were recorded and compared to the list previously 
compiled from the initial QQQ-MS analyses.  In addition, several putative adducts 
42 
 
not seen during initial low-resolution MS analysis were observed by QTOF-MS.  
The compounds deemed of interest also showed the GSH-characteristic ion with 
the mass of m/z (M-H+)- - 272.  As with the QQQ-MS studies, other ions 
previously reported to be characteristic of GSH adducts in negative mode ESI 
were typically present.  
3.6 Identification of Glutathione Adduct Structures 
 Adduct structures were proposed based on accurate mass data for the 
molecular ion of each drug-GSH adduct and for major MS/MS fragments.  
Masses consistent with previously reported adducts were assigned the 
respective structures published in the literature.  For novel adducts, a list of 
metabolites potentially formed in situ was compiled using published metabolism 
data as available and, where not available, the structure of the parent drug was 
altered using common metabolic processes via ChemDraw Prime software 
(PerkinElmer, version 16.0) until a plausible adduct structure was created.  For 
this process, metabolic reactions that were examined included hydroxylation 
(along with NIH shift), O- and N-demethylation, oxidation/reduction, and loss of 
reactive moieties, as these are common for Phase I metabolic pathways.61  
Structures associated with more than one metabolic transformation were also 
considered.  The final theoretical adduct list therefore consisted of multiple target 
structures for each drug.  
Calculated molecular ion masses of the theoretical adduct structures were 
then compared to those observed in the QTOF-MS/MS analysis for each drug to 
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identify tentative positive hits. For these compounds, MS/MS fragmentation data 
were then utilized for further confirmation of adduct structure.  Both GSH- and 
drug-specific fragments were considered in this analysis for maximum confidence 
in the resultant structural assignments.  Where present, exact stereo- and 
regiospecificity of the covalent adduct bond was not identified. 
3.7 Adduction with Hemoglobin 
 The metabolic trapping assay with Hb as a trapping agent required some 
initial optimization. The first utilized assay method involved a cup insert for 
microfuge tubes with a dialysis membrane in the bottom, allowing for passive 
diffusion of smaller molecules. These dialysis membrane cups had not been 
used for this purpose, but were explored as an option because it would allow for 
full separation of the HLM enzymes and the Hb protein without the need for 
additional separation.  
3.7.1 Hemoglobin Trapping Assay Method 
 Adduction with hemoglobin was performed using a trapping assay similar 
to the GSH trapping assay followed by proteolytic digestion by trypsin to produce 
smaller peptides. Briefly, components of the in vitro trapping assay were 
combined in a total assay volume of 250 µL of 25 mM sodium phosphate buffer, 
pH 7.4, at the following final concentrations: 500 μM test drug, 0.5 mg/mL HLM, 1 
mM NADPH, 1.5 mM MgCl2, 1.5 mM G6P, 0.2 units/mL G6PD and 2.5 mg/mL of 
a prepared human Hb solution (5 mg/mL Hb in 25 mM ammonium bicarbonate 
buffer). Drug of interest is added to a clean microfuge tube and solvent is 
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removed via vacufuge. Assay components were then combined in the microfuge 
vial and vortexed briefly to ensure uniformity, the tube was then incubated with 
agitation at 37°C for 6h.  Following incubation, the vial was centrifuged for 30 min 
at 100,000 x g at 4°C. After centrifugation, the supernatant was transferred into a 
clean microfuge tube.  A freshly-prepared 15 mM solution of iodoacetamide 
(IAM) was then added, and the vial was incubated at room temperature in the 
dark for 1 hr.  Following incubation, intact Hb was extracted from the reaction 
mixture via Amicon® Ultra 0.5 mL centrifugal filter spun at 15,000 x g for 10 min.  
Hb was then collected into a new clean microfuge vial and reconstituted in a 1 
mg/mL solution of CaCl2.  A 0.25 mg/mL solution of trypsin was then added, and 
the vial was incubated at 37°C for 16 h.  The vial was then centrifuged for 30 min 
at 100,000 x g at 4°C, and the supernatant collected and placed into a clean LC-
MS vial for analysis.  An illustration of this metabolic trapping assay method is 
found in Figure 10. 
 
Figure 10. Illustration of the metabolic trapping assay method utilizing Hb as a trapping 
agent. 
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3.7.1 Hemoglobin Adduct Analysis 
Analysis of the tryptic peptides was performed using LC-QTOF-MS 
utilizing first full scan mode followed by Auto MS/MS scan mode with positive 
ionization. The full scan mode consisted of no collision energy and only collected 
MS data. The collision energy for the Auto MS/MS analysis was set using the 
equation y=2x+20, where y is the collision energy and x is the mass of the parent 
ion. The masses 121.0388 and 922.0098 were excluded from collection because 
they are the masses of the reference ions used to maintain mass accuracy by the 
instrument. The following parameters were used for both scan mode analyses. 
Column temperature was controlled at 40°C. Elution solvents for the tryptic 
peptide analysis were A: water with 0.1% trifluoroacetic acid and B: acetonitrile 
with 4.9% water and 0.1% trifluoroacetic acid. Injection volume was set to 3 µL. 
Pump parameters were as follows: 0-0.5 min. 10% B, 0.5-18 min. ramp from 5% 
B to 50% B, 18-20 min ramp from 50% B to 100% B, hold at 100% B until 21 
min., followed by a two min. post-run for re-equilibration of the instrument to the 
starting configuration. 
 Analysis of the data collected for the peptide adducts was performed using 
Agilent’s MassHunter BioConfirm software (version B.08.00). The workflow used 
was the “peptide digest” method, the condition was “reduced”, the sequences 
selected were the subunits Hbα and Hbβ, the enzyme selected was trypsin, and 
the modifications were acetylation, hydroxylation, and any appropriate custom 
modifications. The custom modifications were individually created for each drug 
of interest based upon observed adducts from GSH studies and, where GSH 
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data were unavailable, data collected from adduction studies using a synthetic 
peptide (manuscript in progress by Moller, et al).  For the MS studies, once the 
workflow was run the predicted modifications were analyzed, and any potential 
drug adducts were recorded. For the Auto MS/MS studies, the spectra were 
collected, compared to the theoretical peak list supplied by Protein Prospector, 
and confirmed peaks were recorded. Peaks were considered a close match if the 
observed mass was within 0.1 Daltons (Da) of the hypothetical mass reported in 
the theoretical peak table. Peaks were considered a possible match if the mass 
differential was <0.5 Da. All peaks with a mass differential ≥0.5 Da were 
excluded. The workflow for the analysis of the Hb peptide adducts can be found 
in Figure 11. 
 
Figure 11. Flowchart of workflow for Hb peptide adduct analysis. 
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4. Results  
4.1 Task 1: Create and optimize a LC-MS/MS method for the detection and 
characterization of drugs of interest and stable drug metabolites. 
 
4.1.1 Parent Drug Retention Times 
 Optimization of the acquisition method to analyze retention times of the 
parent drugs ensured that a single method could be used for the analysis of all of 
the drugs of interest. Solutions of individual drugs were injected into the 
instrument and the exact mass ([M+H]+) and retention times were recorded 
(Table 7). The overlaid total ion chromatograms (TICs) of 13 of the drugs of 
interest can be found in Figure 12. Several of the compounds had retention times 
very similar to others, and these drugs were separated into different mixtures for 
the next step of this task. The drugs of interest missing from Figure 12 were 
omitted because their TICs were recorded on a different date than the 13 drugs 
pictured. The positive controls APAP and CLZ were recorded separately (Figure 
13), and THC needed to be dissolved in ethanol (Figure 14). Additionally, THC 
could not be identified as a peak without the use of the Find by Formula feature 
of the MassHunter Qualitative software, which targets the specific mass of a 
chemical formula and extracts corresponding peaks from the TIC. This method 
was utilized because THC exhibited poor ionization in positive mode, and 
coeluted with much of the material being flushed through the column by the high 
organic percentage of mobile phase at the end of the run (Figure 14). Because of                                                                                                                                                                                                                                                                           
these issues with the analysis of THC, the extracted ion chromatogram (XIC) for 
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THC was utilized to determine the retention time, which was then added to the 
complete list of the drugs. 
 
Figure 12. A zoomed in portion of the overlaid TICs for α-PVP, ALP, BUP, COC, DZP, 
MDMA, MDPV, META, METH, METY, MOR, NAL and OXY. The peak at approximately 2.1 
min. found in every spectrum is carryover from APAP. 
 
 
Figure 13. TICs for CLZ (top) and APAP (bottom), the two positive controls, used to collect 
their respective retention times. 
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Figure 14. TIC (top) and XIC (bottom) for THC, showing the retention time for THC. 
 
 
4.1.2 Parent Drug Fragmentation 
 After the collection of all retention times and exact masses observed by 
the instrument for each parent drug, the five mixtures of non-coeluting parent 
drugs were analyzed. The instrumental method used for analysis of the mixtures 
utilized targeted MS/MS mode, but all other parameters remained the same. The 
mixtures created can be found in Table 6.  
Mixture Drugs Included 
Mixture #1 APAP, METH, COC 
Mixture #2 MDMA, α-PVP, DZP 
Mixture #3 META, METY, MDPV 
Mixture #4 ALP, MOR, OXY 
Mixture #5 BUP, NAL, THC 
Table 6. Mixtures of parent drugs created to collect transitions 
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CLZ was not included in the original mixtures, but was run individually. 
The TIC for each mixture (Figure 15) was analyzed using the Find by Targeted 
MS/MS feature on Masshunter Qualitative software. The collected spectra for 
each collision energy (10, 20, or 40 eV) were analyzed separately to ensure that 
a complete list of fragments could be identified. It was necessary to collect these 
data so it would be possible to apply the same fragmentation patterns to 
proposed adducts at later stages of this research. The MS/MS data collected for 
the parent drugs can be found below in Figure 16. Table 7 was created by 
combining the information from the retention time experiments and the transition 
experiments for all of the drugs of interest. Many drugs had transitions with the 
same m/z, but are distinguishable by the other recorded transitions or retention 
times. 
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Figure 15. Targeted MS/MS TICs for the five mixtures of the parent drugs. 
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Figure 16. MS/MS data for the parent drugs. The data are shown at 10 eV (top), 20 eV 
(middle), and 40 eV (bottom) for each drug. 
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 Formula [M+H]
+ Ret. Time Tran. 1 Tran. 2 Tran. 3 
α-PVP C15H21NO 232.170 4.48 161.094 126.126 91.053 
APAP C8H9NO2 152.071 2.14 110.060 93.034 65.039 
ALP C17H13ClN4 309.090 5.58 281.070 274.117 205.073 
BUP C29H41NO4 468.311 5.18 414.257 396.213 55.054 
CLZ C18H19ClN4 327.147 4.88 270.089 227.045 192.075 
COC C17H21NO4 304.154 4.59 182.115 105.033 82.064 
DZP C16H13ClN2O 285.079 6.28 193.089 154.042 91.054 
MDMA C11H15NO2 194.118 3.93 163.074 135.043 77.038 
MDPV C16H21NO3 276.159 4.58 205.083 175.072 126.126 
META C21H27NO 310.217 5.57 265.156 105.033 77.038 
METH C10H15N 150.128 3.79 119.083 91.053 65.038 
METY C11H13NO3 208.097 3.56 190.085 160.075 132.080 
MOR C17H19NO3 286.144 1.41 229.085 201.090 165.069 
NAL C20H23NO4 342.170 3.82 324.156 267.112 55.054 
OXY C18H21NO4 316.154 3.78 298.141 256.132 241.108 
THC C21H30O2 315.232 7.78 259.174 193.126 135.119 
Table 7. Retention time and fragmentation data collected for all 16 drugs of interest in this 
research. Retention time is in minutes. Transitions collected were the three most 
prominent across all collision energies. 
 
 
 
4.1.3 Stable Drug Metabolites 
 Attempts to simplify the metabolic assay used for the stable drug 
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metabolites involved excluding the regeneration system for the NADPH. Initial 
experiments analyzing the stable metabolic assay did not utilize G6P and G6PD, 
and therefore produced poor results. The addition of the regeneration system 
yielded significantly better results and were then applied to the metabolic assay 
with clozapine.  
When utilizing clozapine for metabolism studies, there are generally two 
major metabolites produced, clozapine N-oxide and N-desmethylclozapine 
(Figure 17).129 Following the in vitro metabolic assay performed, there were two 
peaks present in the TIC which were not present in the negative controls (Figure 
18). Both of these new peaks corresponded to the major metabolites for 
clozapine, with m/z of 343.1182 for clozapine N-oxide and 313.1220 for N-
desmethylclozapine. Their XIC data can be seen in Figure 19.  
  
Figure 17. Two major metabolites for clozapine, clozapine N-oxide (left) and N-
desmethylclozapine (right) with their exact masses. 
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Figure 18.  The TICs for the in vitro metabolic assay for clozapine (top) and the negative 
control with no metabolic system (bottom). The two new peaks are labeled with their 
corresponding metabolite. 
 
 
 
Figure 19. XIC data for N-desmethylclozapine (top) and clozapine N-oxide (bottom). 
 
The stable metabolite data for COC also showed two prominent metabolites, 
benzoylecgonine and cocaethylene. These data can be seen in Figures 20 and 21. The 
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observation of the metabolites for both CLZ and COC implied that the metabolic 
system utilized would be able to successfully produce the expected metabolites 
of the drugs of interest. 
 
Figure 20 The TICs for the in vitro metabolic assay for COC; the two new peaks are labeled 
with their corresponding metabolite. 
 
Figure 21 XIC data for cocaethylene (top) and benzoylecgonine (bottom). 
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4.1.4 Task 1 Discussion 
 The purpose of this task was to characterize the parent drugs of abuse 
selected for this study and to assess the effectiveness of the in vitro metabolic 
assay. To discover how the drugs would behave during the instrumental analysis 
procedure, retention times were determined for all of the drugs. The positive 
control acetaminophen is not completely soluble in methanol. This led to 
acetaminophen being retained on the column and eluting into subsequent 
sample runs taken that day, as can be seen in Figure 12. Fortunately, this did not 
interfere with the retention times of any of the other drugs of interest. THC also 
did not elute at a time similar to the other compounds, and instead was detected 
towards the end of the run when a high percentage of organic mobile phase was 
running through the column. This led to no visible peak for THC, a problem which 
was remedied by the Find by Formula feature of MassHunter’s Qualitative 
software (Figure 14). This may be due to THC being poorly ionized in positive 
mode, with negative ionization generally being favored for THC analysis.130 
 The fragmentation collected for each drug of interest was obtained in 
hopes that it would provide insight into the possible fragmentation patterns of any 
adducted moieties in later studies. All fragmentation data was collected in 
positive mode, as many of the drugs experience poor ionization using negative 
mode analysis. While analysis shifted from positive to negative ionization with the 
GSH adduct studies, the fragmentation collected in Task 1 will be useful in any 
future GSH research utilizing positive ionization mode analysis of adducts.  
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In order to progress to the subsequent tasks of this research, stable 
metabolite analysis was only preformed using clozapine. While clozapine may 
have as many as five observed stable metabolites, clozapine N-oxide and N-
desmethylclozapine are the most prevalent and were the two metabolites 
pursued in this task.131 These two stable metabolites have been observed in 
plasma at concentrations approximately the same as the parent drug.132 The 
identification of these two compounds allowed for advancement to the 
implementation of reactive metabolite assays containing trapping reagents. 
4.2 Task 2: Create and optimize a LC-MS/MS method for the detection and 
characterization of reactive drug metabolites. 
 
4.2.1 Metabolic Trapping Assay Optimization 
 Optimization of the in vitro assay system required numerous factors to be 
examined.  Incubation times of 1, 3, 6, and 12 h were examined, with 3 h 
determined to be optimal for maximum production of primary metabolites and 
minimal formation of secondary products.  As reported by other investigators84, 
glutathione-S-transferase (GST) was included in several trials to determine if its 
presence would aid in the formation of adducts with GSH.  However, there was 
no observed increase in adduct formation, and GST was therefore eliminated 
from the protocol for simplicity.  The addition of G6P and G6PD provided a 
regeneration system for NADPH which allowed for optimal enzymatic activity for 
the duration of the incubation.  Initial trials were conducted with a drug: GSH 
molar ratio of 1:20, however this was later changed to 1:2 (final concentration as 
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stated in Methods) by increasing the concentration of the drug of interest in order 
to maximize the concentration of the reactive metabolites formed. Even though 
this is not an accurate approximation of biologically relevant drug concentrations, 
it was determined that this amount would provide the greatest opportunity for 
adduct formation. 
4.2.2 MS and MS/MS Analysis of Glutathione Adducts 
Figure 22a shows an example of a product ion TIC for the positive control drug 
APAP.  A large peak is present at RT ~2.6 min; the inset shows numerous 
additional potentially relevant peaks at lower abundances.  XIC analysis of 
APAP-adducted GSH (Figure 22b) revealed one major product at RT 2.68 min 
with m/z 455 and a minor product at RT 2.36 min with m/z 471. Bot of the APAP-
GSH adducts identified in this experiment have been previously reported.80,88 
The precursor ion scan TIC  and XIC data for the remaining drugs can be found 
in Appendix 1. 
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Figure 22. (A) TIC of APAP+GSH collected by product ion scan mode via LC-QqQ-MS in 
negative ionization mode.  Inset is zoomed-in portion around the base of the major peak, 
showing multiple peaks with lesser intensities.  (B) XICs for ions at m/z 471 and 455, the 
two relevant peaks of interest from the TIC. 
 
Using this approach, a total of 20 potentially significant GSH adduction 
products were identified by LC-QqQ-MS/MS analysis for 10 of the 16 drugs 
examined, including APAP, CLZ, COC, DZP, MDMA, MDPV, MOR, NAL, OXY, 
and THC. Multiple adduct structures were also observed for a number of drugs.  
In contrast, GSH adducts were not observed for ALP, BUP, DZP, META, METH, 
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and METY under the conditions used in the study.  Target products detected by 
low resolution MS were then further examined using high resolution LC-QTOF-
MS/MS analysis as described below.  These potential adducts, and those 
observed by LC-QTOF-MS/MS analysis, are summarized in Table 8. 
 
Table 8. Theoretical adduct masses collected via QQQ-MS/MS and QTOF MS/MS. 
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 Figure 23 shows the high-resolution mass spectrum of GSH, with 
corresponding fragment structures indicated.  Table 9 presents HRMS data 
(molecular formula, molecular ion and characteristic fragment ions, and proposed 
composition) for all GSH adducts detected in the study, along with literature 
reference if previously reported.  The presence and relative abundance of 
characteristic GSH fragments (i.e., “b”, “f”, “i”, and “k” ions) and fragments 
associated with drug still bound to GSH (i.e., “d” and “j” ions) provided important 
data to further elucidate adduct identity and location of the drug-thiol 
linkage(Figure 24).88 In addition, ions associated with fragmentation within the 
drug moiety itself were occasionally observed.  Structural elucidation was 
facilitated by the generation of fragments at collision energies of 10, 20, and 40 
eV (i.e., top, middle, and bottom panels of each adduct MS/MS spectrum in 
Figure 25). All MS/MS data for adducts previously reported in the literature are 
confirmed in Figure 26. 
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Figure 23. LC-QTOF-MS/MS data collected for glutathione.  The peaks labeled all 
correspond to a known characteristic GSH peak.  Negative ionization structures for each 
peak are provided for each peak. 
 
Figure 24. Detailed breakdown of the nomenclature used for the fragmentation of the GSH 
adducts. Data presented are from Xie et al.88 
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Figure 25. MS/MS spectra for all 12 previously unreported adducts.  The molecular ion is 
represented in blue, GSH-specific peaks in green, and structurally significant peaks for 
GSH-containing compounds in red.  Proposed structures for 9 of the 12 adducts are also 
shown with GSH linkage indicated. 
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Figure 26. MS/MS data collected for all previously reported GSH adducts 
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Drug Formula Composition Ions Observed Reference 
 C10H17N3O6S GSH 306.095, 272.106(k), 254.094, 210.103, 179.059, 160.020, 143.058(b), 128.046(f)  
APAP1 C18H24N4O8S D+GSH-2H 455.089, 272.089(k), 254.078, 210.088, 182.028(d), 143.045(b), 128.046(f) 74 
APAP2 C18H24N4O9S D+GSH+O-2H 471.119, 272.088(k), 198.025 (d), 143.045(b), 128.045(f) 82 
CLZ1 C28H34ClN7O6S D+GSH-2H 630.194, 357.095(d), 272.089(k), 254.078, 143.046(b) 75 
CLZ2 C28H36ClN7O7S D+GSH+O 648.198, 272.089(k), 143.046(b) 75 
CLZ3 C23H24ClN5O7S D+GSH+O-C5H10N2 548.101, 275.005(d), 272.095(k), 143.046(b) None 
COC1 C27H38N4O11S D+GSH+O 625.230, 565.055, 384.821, 306.080(i), 272.090(k), 194.950, 143.046(b) 57 
DZP1 C26H30ClN5O8S D+GSH+O 606.154, 588.142, 315.039, 272.088(k), 258.013, 210.089, 143.046(b) None 
MDMA1 C20H30N4O8S D+GSH-CH2 485.189, 272.090(k), 212.771(d), 143.047(b), 128.045(f) 78 
MDMA2 C21H30N4O8S D+GSH-2H 497.131, 272.091(k), 254.085, 143.047(b), 128.046(f) 78 
MDMA3 C19H25N3O9S D+GSH+O-C2H7N 470.140, 436.793, 272.090(k), 197.030(d), 143.046(b), 128.045(f) 78 
MDPV1 C25H36N4O9S D+GSH-CH2 567.238, 294.118(d), 272.091(k) 78 
MDPV2 C21H29N3O9S D+GSH-C5H8N 498.172, 272.089(k), 225.060(d), 143.046(b), 139.995 None 
MDPV3 C21H29N3O10S D+GSH+O-C5H7N 514.168, 378.808, 272.103(k), 241.068(d), 143.056(b)  None 
MOR1 C27H34N4O9S D+GSH-OH 589.219, 316.102(d), 306.077(i), 272.089(k), 210.089, 143.046(b), 128.045(f) 54 
NAL1 C30H38N4O10S D+GSH-2H 645.249, 306.094(i), 272.105(k), 210.089, 143.057(b), 128.046(f) None 
NAL2 
C30H40N4O11S D+GSH+O 663.260, 390.157(d), 358.184(j), 306.093(i), 272.105(k), 210.089, 143.057(b), 
128.046(f) 
None 
OXY1 C28H36N4O10S D+GSH-2H 619.208, 408.012, 306.077(i), 272.958(k), 210.089, 143.057(b), 128.046(f) None 
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aMolecular ion in bold; letters in parentheses refer to characteristic GSH fragments according to nomenclature of Xie et al. (2013). 
bLiterature reference for previously reported adduct; none – not previously reported. 
Table 9. Summary of fragmentation of all GSH adducts observed. 
 
 
 
 
 
 
OXY2 C28H34N4O11S D+GSH+O-4H 633.223, 306.076(i), 272.088(k), 210.089, 143.057(b), 128.046(f) None 
THC1 C31H45N3O9S D+GSH+O-2H 634.306, 361.205(d), 306.095(i), 272.106(k), 210.091, 143.058(b), 128.046(f) None 
THC2 
C31H45N3O10S D+GSH+O2-2H 650.301, 377.199(d), 343.193(j), 306.094(i), 272.106(k), 210.091, 143.057(b), 
128.046(f) 
None 
THC3 
C31H45N3O11S D+GSH+O3-H 666.297, 393.195(d), 359.190(j), 306.094(i), 272.106(k), 210.091, 143.057(b), 
128.046(f) 
None 
THC4 C31H41N3O12S D+GSH+O4-4H 678.304, 306.095(i), 272.106(k), 210.091, 143.058(b), 128.046(f) None 
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4.2.3 Glutathione Adduct Structure Identification 
 As an example of the procedure used to confirm GSH adduct formation 
and identity based on HRMS data, the molecular ion peak observed at m/z 
455.089 for APAP was consistent with a previously reported adduct of the parent 
drug with GSH (APAP1; Figure 27a and Table 9) Major fragment ions for this 
adduct included the molecular ion (m/z 455.089), five fragments specific to GSH 
(m/z 272.089, 254.078, 210.088, 143.045, 128.046)88, and a fragment 
corresponding to the drug moiety bound to the sulfur of GSH (m/z 182.028).  A 
second, less intense molecular ion peak for an acetaminophen-GSH adduct 
(APAP2) was observed at m/z 471.119, along with three fragments consistent 
with GSH modification (m/z 272.088, 143.045, and 128.045) in addition to a 
fragment corresponding to the drug moiety bound to the sulfur of GSH (m/z 
198.025) (Figure 27b and Table 9).  To determine potential structures for this 
adduct, the parent drug was subjected to manual metabolic modification analysis 
using ChemDraw Prime software (PerkinElmer, version 16.0) to produce a list of 
likely alterations occurring from Phase I metabolism.  This analysis indicated that 
hydroxylation of the phenyl ring would produce calculated molecular ion and 
fragment masses consistent with those observed.  This proposed most likely 
adduct structure has also been previously reported.88 
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Figure 27. MS/MS data collected for APAP1 and APAP2. 
 
The same general procedure was repeated for all detected putative drug-
GSH adducts.  Figure 25 shows QTOF MS/MS spectra and proposed structures 
for all GSH adducts identified in the present study that have not been previously 
reported in the literature.  For clozapine, three GSH adducts were detected.  
Data for two of these (CLZ1 and CLZ2) are consistent with adducts previously 
reported by other investigators.  In contrast, CLZ3 (Figure 25) represents a novel 
79 
 
GSH adduct structure for this drug.  For CLZ3, the [M-H]- ion with m/z of 548.099 
is consistent with loss of the entire piperazine moiety, in addition to hydroxylation 
and rearomatization following adduction with GSH.  The peak labeled as a “d” 
transition at m/z 275.005 corresponds to the neutral loss observed from the 
cleavage of the sulfur of GSH from the rest of the tripeptide.  The resulting 
fragment represents the metabolized CLZ moiety still bound to the sulfur of GSH.  
The “k” ion corresponds to a characteristic GSH fragment. Rearomatization of the 
benzene ring is supported by the presence of the “k” peak and lack of an “i” peak, 
suggesting that conjugation occurs at an aromatic site on the clozapine 
metabolite.88 
DZP1 is a previously unreported adduct for diazepam and was the only 
one observed for this drug.  The presence of the [M-H]- ion at m/z 606.154 is 
consistent with a mechanism involving reduction of the diazepine ketone in the 
parent drug to a hydroxyl group, hydroxylation of the 5-phenyl ring, and covalent 
adduction of GSH with rearomatization of the phenyl group.  The specific 
fragment at m/z 588.142 is consistent with cleavage of a hydroxyl group, most 
likely that attached to the 5-phenyl moiety.  The specific fragment at m/z 315.044 
may be derived via cleavage of both the 5-phenyl hydroxyl and the phenyl C-S 
bond of the adduct.  Rearomatization of the phenyl ring containing the site of 
adduction is supported by the presence of the “k” fragment at m/z 272.098 in 
addition to the lack of an “i” fragment.  The remaining “b” and m/z 210.093 ions 
are each consistent with GSH fragmentation. 
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MDPV1 is identical in MS/MS characteristics to a previously reported GSH 
adduct with this compound and which represents adduction to a demethylenated 
diol metabolite.84 MDPV2 is the first of two previously unreported MDPV adducts 
observed in this study.  The [M-H]- ion at m/z 498.172 most likely represents 
metabolic demethylenation, as with MDPV1, in addition to further metabolic loss 
of the pyrrolidine ring via N-deamination, followed by covalent adduction by the 
GSH thiol on the phenolic ring.  The presence of a “d” fragment at m/z 225.060 
further supports the identity of the adducted drug moiety, as it corresponds to the 
mass of the moiety plus the sulfur of GSH.  The presence of a “k” fragment with 
m/z 272. 089 and lack of a detectable “i” fragment strongly indicates linkage of 
the GSH sulfur to an aromatic carbon.  The remaining “b” ion at m/z 143.046 
represents a GSH fragment.  
MDPV3 is a second unreported GSH adduct for this compound.  Similar to 
MDPV2, the [M-H]- ion at m/z 514.168 is consistent with demethylenation, loss of 
the pyrrolidine ring, and covalent adduction of the GSH thiol.  However, the 
precursor ion mass for MDPV3 also indicates addition of a hydroxyl group, most 
likely on the alkyl chain moiety.  This interpretation is corroborated by the 
presence of a “d” ion with m/z 241.068.  Again, the presence of a “k” fragment at 
m/z 272.103 along with the lack of an “i” fragment supports an aromatic thiol 
linkage.  The remaining “b” ion represents a GSH fragment, while the ion at m/z 
378.808 is unidentified. 
Two naltrexone-GSH adducts were observed in the present study and are 
the first such derivatives reported in the literature.  For NAL1, a [M-H]- ion at m/z 
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645.249 is consistent with unmodified precursor drug directly adducted to GSH.  
The MS/MS spectrum clearly shows the presence of “k” ions with lower 
intensities of “i” and “d” ions (Figure 25).  While not unequivocal, this pattern is 
most consistent with thiol conjugation to the benzene ring in naltrexone.  The “f” 
and “b” ions represent GSH fragments.  
The MS/MS spectrum for NAL2 exhibits an [M-H]- ion at m/z 663.260, 
which is most consistent with GSH conjugation to a hydroxylated metabolite.  
This interpretation is also supported by the presence of a “d” fragment at m/z 
390.157 and a “j” fragment at m/z 358.184. The similar relative abundances of 
the “k” and “i” ions along with the higher abundance of “d” as compared to “j” ions 
suggest linkage of the thiol sulfur of GSH to an aliphatic carbon in the drug 
moiety.88 While Figure 25 shows one possible structure consistent with these 
data, the position of the hydroxyl group and C-S link cannot be unequivocally 
determined without additional information. 
GSH adducts with oxycodone have not previously been reported.  In the 
present study, OXY1 exhibited a [M-H]- ion at m/z 619.208, consistent with GSH 
adduction to parent drug.  The presence of an “i” fragment at m/z 306.077 at a 
much higher abundance than the “k” ion at m/z 272.958, along with the absence 
of a “d” ion, is strongly suggestive of a GSH thiol linkage to a benzylic carbon. 
This determination of a benzylic linkage is in agreeance with the literature on 
GSH adduct linkage sites.88 Based on these data, a possible structure for the 
OXY1 adduct is shown in Figure 25.  Evidence for a second GSH-oxycodone 
adduct (OXY2) was also obtained.  The [M-H]- ion at m/z 633.223 is 14 Da larger 
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than the OXY1 species, suggesting GSH adduction to a metabolite of the drug.  
As with OXY1, the presence of a high abundance “i” fragment at m/z 306.077 
combined with the lack of a “d” ion is strongly suggestive of a GSH thiol linkage 
to a benzylic carbon.  However, without additional data, a putative structure for 
this adduct is not proposed. 
GSH adducts of 9-tetrahydrocannabinol (THC) have not previously been 
reported in the literature.  The present study identified four species consistent 
with covalent adduction of GSH with THC, all proposed to result from 
modification of THC metabolites oxidized at the 11 position or on the pentyl chain 
of the parent drug.  THC1 exhibited a [M-H]- ion at m/z 634.306, consistent with 
GSH adduction to 11-hydroxy-Δ9-THC, a prominent metabolite of this 
cannabinoid.88 The presence of a major “d” ion at m/z 361.205 in addition to the 
“i” fragment further supports this interpretation.  The data most support a benzylic 
C-S linkage between the drug moiety and GSH, based on the substantially higher 
intensity of the “i” fragment as compared to that of the “k” ion (Figure 25).  
However, due to the presence of a definite “d” fragment, an aliphatic linkage 
cannot be entirely ruled out.  
The THC2 moiety exhibited a [M-H]- ion at m/z 650.301, which is 
consistent with conjugation of GSH with another common THC metabolite, i.e., 
11-nor-9-carboxy-Δ9-THC.  This interpretation is also supported by the presence 
of a “d” fragment at m/z 377.199.  The covalent linkage between the drug moiety 
and the GSH sulfur is most likely aliphatic, since the intensity of the “k” ion (at 
m/z 272.106) is higher than that of the “i” fragment at m/z 306.094. 
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The structures of the detected adducts represented by THC3 and THC4 
are more speculative, as they appear to involve adduction of secondary oxidized 
THC metabolites.  For example, THC3 exhibited a [M-H]- ion at m/z 666.297, 
which would be consistent with GSH adduction to a hydroxylated metabolite of 
11-nor-9-carboxy-Δ9-THC, a conclusion further supported by the presence of the 
drug-specific “d” fragment at m/z 393.195.  The lack of prominent “i” ions in the 
spectrum suggests linkage of aromatic carbon to the GSH sulfur.  The MS/MS 
spectrum of THC4 exhibited a [M-H]- ion at m/z 678.334, i.e., 38 Da higher than 
observed for THC2.  This observation would be consistent with GSH adduction to 
a metabolite of 11-nor-9-carboxy-Δ9-THC containing a second carboxyl function.  
Furthermore, the appearance of “i” ions at much higher intensity than “k” ions, in 
addition to the absence of “d” ions in this spectrum, suggests a linkage of the 
GSH sulfur to a benzylic carbon.  Nevertheless, additional data are required to 
identify the exact nature of the metabolic modifications present in the THC3 and 
THC4 adducts and the location of the C-S linkage in each species. 
4.2.4 Task 2 Discussion 
 This task explored the capability of selected drugs of abuse to form adducts 
with the tripeptide glutathione.  The formed adducts result from covalent bonds 
between the nucleophilic sulfur in GSH and an electrophilic site on the parent 
drug or a metabolite.  The formation of GSH-based adducts with drugs of abuse 
has only been sparingly reported in the literature, with available data limited to 
cocaine61, MDMA and MDPV84, and morphine58.  In these examples, MDMA was 
the only compound with reported GSH adducts formed by both the precursor 
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drug and a metabolite.  While previous work with these drugs has demonstrated 
the capability to form adducts with GSH, there is clearly a lack of available 
information on this phenomenon for other widely abused substances. 
 Of the 22 GSH adducts observed in this study, nine have been previously 
reported in the literature (see Table 9 for references).  The structures reported 
previously all have masses which match closely with those observed in spectra 
collected in the present study.58,61,80,81,84  A direct comparison of our spectral data 
with previous reports is possible for MDMA and MDPV, where negative mode MS 
ionization and analysis was also utilized.  MS/MS data for fragments of GSH and 
GSH containing compounds and molecular ion exact masses observed for 
MDMA1, MDMA2, MDMA3, and MDPV1 in the present study agree with the data 
previously reported with negative mode analysis.84 
  Plausible structures are proposed for the majority of the previously 
unreported adducts identified in the present study, based upon HRMS accurate 
mass, MS/MS data, and likely metabolic transformations.  However, for the 
OXY2, THC3, and THC4 adducts, the available data were insufficient to propose 
a structure with a high degree of confidence.  The fragmentation patterns 
suggest that both OXY2 and THC4 have benzylic covalent thiol linkages, while 
THC3 likely contains an aromatic linkage.  The molecular ion masses of THC3 
and THC4 seem to suggest further metabolic modifications to the metabolite 11-
nor-9-carboxy-Δ9-THC prior to covalent adduction with GSH, such as a 
hydroxylation or further carboxylation.  OXY2 also appears to have undergone  
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additional metabolic modification prior to adduction, although the exact steps are 
unclear. 
 While NAL1 and OXY1 have an adduct mass which corresponds to the parent 
drug directly bound to GSH without any other modifications, the other structures 
proposed for GSH adducts in Table 9 represent adducts formed by one or more 
primary metabolites of the drug.  One of the initial metabolic steps is likely to be 
hydroxylation, as is consistent with the proposed structures for CLZ1, DZP1, 
MDPV3, and NAL2.  Hydroxylations are common oxidative steps in the metabolic 
pathways of CLZ, DZP, and MDPV, although this pathway has not been reported 
for NAL.129,133,134 
 Structures consistent with bond cleavage within the drug moiety were also 
observed for three of the adducts. CLZ3 is proposed to have lost the piperazine 
ring in addition to undergoing hydroxylation and rearomatization.  While this 
particular metabolite has not previously been reported in the literature, there 
have been observations of modifications to the piperazine ring in CLZ, indicating 
that it may be a site of potential metabolic processes resulting in loss of 
piperazine ring.135  Loss of a piperazine ring has been exhibited in the 
metabolism of other heterocycle containing compounds such as aildenafil.136  
Formation of MDPV2 is associated with loss of the methylene bridge and 
pyrrolidine moiety (via oxidative deamination) in addition to rearomatization, while 
MDPV3 may form via the same process in addition to a hydroxylation on the 
resultant alkyl chain.  Demethylenation, common to either the orthocatechol or 
orthoquinone, and oxidative deamination of methylenedioxy type drugs has been 
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reported in the literature.84,134 The orthoquinone formed by some methylenedioxy 
drugs has been reported to be the reactive metabolite responsible for toxicity.87  
As mentioned previously, some of the drugs underwent a rearomatization step 
following GSH adduction and NIH shift (CLZ1, MDPV1, MDPV2, NAL1, OXY1, 
THC1, and THC2) while others did not (DZP1 and NAL2).  This observation is 
similar to what has been generally reported in the literature involving NIH shifts19.  
 GSH adducts with ∆9-THC have not been previously reported.  The proposed 
structures for THC1 and THC2 are consistent with adducts formed from the 
stable metabolites 11-OH-∆9-THC and 11-nor-9-carboxy-∆9-THC, respectively, 
with direct binding to GSH.  The fragmentation patterns and peak ratios 
discussed in the Results section indicate the thiol linkages appear to be benzylic 
for THC1 and aliphatic for THC2.  The fact that these adducts are consistent with 
the stable metabolites implies that there may be a reactive intermediate formed, 
allowing for electrophilic interactions with the thiol moiety from GSH. 
 For the MS analysis of the GSH compounds in the present study, negative 
mode scanning was utilized.  This was chosen primarily to facilitate analysis of 
adducted GSH fragmentation. GSH fragmentation patterns in negative mode are 
well-established in the literature, and in fact have been studied for a variety of 
covalent adducts, including those with aromatic, aliphatic, and benzylic 
linkages.88,110 The observed transitions also provided more prominent and 
clearer ion signals than those following initial analyses utilizing positive mode 
scanning.  Additionally, many of the parent drugs included here do not produce 
prominent molecular ions or fragment ions in negative mode, thus minimizing 
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potential interferences due to coelution with unreacted drug present in the assay 
mixture at significantly higher concentrations than the formed adducts.  While 
positive mode analysis of the novel GSH adducts could provide additional data 
for structural confirmation, preliminary use of positive mode for several of the 
drugs in the present study did not provide useful fragmentation data.  As other 
authors have reported, positive mode ionization is not always helpful for 
characterization of GSH adducts, particularly with certain drugs where doubly 
charged [M+2H]+ ions are formed, as these do not allow for the neutral loss 
analysis which is generally utilized in positive mode GSH studies.110 Although 
negative ionization mode alone did not provide the data necessary for complete 
structural analysis of all adducts, this approach did provide sufficient information 
to determine a plausible adduct structure for most of the drugs under study.  
Unequivocal structural confirmation, including identification of regioselectivity of 
adduct formation where present, will require additional work with synthetic 
standards and further analysis by HRMS and definitive techniques such as NMR.   
4.3 Confirmation of adduction in human Hb by drugs of interest 
4.3.1 Protein Adduction Assay Optimization 
 Optimization of the in vitro assay system for protein adduction required 
numerous alterations from the previous assay used for GSH. Incubation time was 
increased to six hours to provide more time for interactions between the 
hemoglobin and the reactive metabolites. Several initial experiments utilized 
various products containing a dialysis membrane layer as an attempt to separate 
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the hemoglobin from the metabolic system. The use of dialysis membrane 
microfuge inserts required significant scale up (approximately x10), and were 
deemed non cost-effective. Dialysis membrane layers were then abandoned in 
favor of ultra-fast centrifugation to pellet the HLM while the hemoglobin remained 
suspended in the solution. Concentrations of IAM and trypsin were established 
based on existing protocols in the literature regarding similar proteolytic 
digestions.137  
4.3.2 Analysis of Hemoglobin Trapping Assay Products 
 The full scan analysis of the tryptic digestion assay supernatant produced 
a complex TIC (figure 28a). BioConfirm software was able to remove compounds 
not relevant to the formed tryptic peptides to produce a total compound 
chromatogram (TCC). The software then analyzed the TCC (Figure 28b) for 
expected peptides, peptide fragments, and any modifications allowed for in the 
sample processing method found in Figure 30 (full Bioconfirm method 
parameters found in Figure 29). Each drug-related adduct modification was 
manually input into the BioConfirm method based upon the observed masses 
from the GSH and synthetic peptide studies. Once completed, BioConfirm output 
a list of biomolecules found in the data. The MS data analyzed with BioConfirm 
produced positive results for the adduction of APAP, for the first time confirming 
via MS data what had been reported previously in the literature using 
radiolabeling and HPLC studies.125,138 In fact, APAP adduction was observed for 
both Hb β93Cys and the less reactive Hb β112Cys. Adduction was also observed 
via MS data for α-PVP, METH, NAL, OXY, and THC, producing a total of 11 
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potential adducts. A summary of all of the BioConfirm data for all of these 
adducts can be found in Table 10. The mass difference, presented in ppm units, 
falls within an acceptable range for all but three of the 11 adducts observed in the 
MS studies. Generally, a TOF is capable of <5 ppm measurments139; only 
adducts 6, 9, and 11 fell outside of this range.  Five of the potential adducts were 
also reported by BioConfirm to contain more than one modification on the 
analyzed peptide (i.e. an additional hydroxylation and/or acetylation). These 
additional modifications lower the certainty of the presence of adducts 5, 6, 9, 10, 
and 11, but was not enough to eliminate these as potential adducts. 
 
 
Figure 28. TIC (a) and TCC (b) for the APAP+Hb adduct. The removal of certain peaks was 
accomplished using the BioConfirm software. 
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Parameter Value  
Extraction algorithm Small Molecules 
Restrict m/z to  350-2000 
Use peaks with height 100 counts 
Positive ions +H, +Na, +K, +NH4 
Neutral losses H2O 
Isotope model Peptides 
Mass filters  none 
Maximum number of peaks 50 largest 
Figure 29. BioConfirm method parameters. 
 
 
Figure 30. The BioConfirm sample processing method utilized for the adducted tryptic 
peptides. Modifications and profiles included the modifications for acetylation, 
hydroxylation, and the adducted drug moieties observed in the GSH experiments or 
synthetic peptide experiments performed by Dr. Carolina Moller (publication pending).  
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Adduct 
Adduction 
Site 
Other Mods Δm/z (ppm) 
Adducted Peptide 
Mass 
1 APAP1 Hb β93  none 2.93 1569.718 
2 APAP1 Hb β112  none -3.29 1868.0069 
3 α-PVP1 Hb β93  none -3.63 1651.822 
4 METH1 Hb β93  none -4.63 1597.7632 
5 METH1 Hb α104 1Hydrox.+1Acetyl. 3.36 3171.7261 
6 METH1 Hb β93  1Acetyl. 5.14 1609.7728 
7 NAL1 Hb β93  none -0.61 1759.8117 
8 OXY1 Hb β93  none 3.57 1733.8033 
9 OXY1 Hb α104 1Hydrox.+1Acetyl. 7.84 3337.7682 
10 THC1 Hb β93  1Hydrox.+1Acetyl. 4.34 2914.4338* 
11 THC2 Hb β93  1Hydrox. -7.16 1780.8466 
 
Table 10. Summary of MS data collected for Hb adducts. The asterisk for adduct 11 
indicates a missed tryptic cleavage in the identified adduct. 
 
4.3.3 MS/MS Analysis of Hemoglobin Adducts 
 Each drug which produced a potential adduct was additionally subjected 
to MS/MS analysis using the Auto MS/MS scan mode data. BioConfirm 
successfully identified MS/MS fragmentation for two of the adducts from Table 
10, APAP1 modified Hb β93 and α-PVP1 modified Hb β93. While BioConfirm is 
capable of labeling individual amino acids and both b and y fragments in 
accordance with the a,b,c and x,y,z nomenclature, it fails to label any other peaks 
which may be pertinent. Therefore, each spectrum was manually compared to a 
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list of theoretical peaks provided by the MS-Product program of Protein 
Prospector (http://prospector.ucsf.edu). Protein Prospector is an online series of 
tools used for proteomic data mining specifically with mass spectrometry. The 
programs were developed by the University of California at San Francisco Mass 
Spectrometry Facility. The parameters used to compile the theoretical peak table 
can be found in Table 11.   
Parameter Value 
Sequence Based on hypothesized match done by BioConifrm 
software 
Modification represented by cysteine residue followed by 
parentheses containing the exact mass of the modification 
N-term Sequence a, b, c 
C-term Sequence x, y, z 
Internal Fragment Allow for internal fragmentation 
Neutral-loss 
Sequence 
-H2O (S, T, E, D) 
-NH3 (R, K, Q, N) 
Peeling 
Sequence 
B+H2O (R, H, K) 
Max Charge 2 
Mass Type Monoisotopic 
Instrument ESI-Q-TOF 
Table 11. Protein Prospector parameters 
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 In the BioConfirm data for the APAP adduct with Hb, 11 peaks were 
identified in the MS/MS spectrum (Figure 31). Using the potential peak list 
populated by Protein Prospector, 18 additional peaks were identified. The 
resulting 29 peaks along with the corresponding fragment can be found in Table 
12. The MS/MS data of the negative control unmodified peptide chain can be 
found in Figure 32.   
 
 
Figure 31. MS/MS identification of the adduct formed between APAPand Hb β93. (A) 
BioConfirm labeled MS/MS spectrum 11 peaks in the spectrum with the b fragment in blue, 
the y fragments in red, and the amino acid histidine shown in green. (B) Putative structure 
of APAP adduct. (C) Peptide fragmentation diagram for MS/MS data. 
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Fragment Mass Fragment Fragment Mass Fragment 
110.0713 H 593.3293* TFATLS-28 
120.0808 F 633.2573 y4-H2O 
145.0972 AT-28 651.2678 y4 
147.1128 y1 729.2784 ELHC(+149.06)D-H2O 
217.0819 SE 747.3254 y5-NH3 
257.6081+2* y3+2 764.3519 y5 
288.1343 b3-H2O 785.8701+2 MH+2 
359.1714 b4-H2O 835.456 TFATLSEL-28 
433.2445 FATL 876.368 y6-NH3 
439.23 SELH-28 980.4265 y7 
460.2191 b5-H2O 982.4993 TFATLSELH-H2O 
467.2249 SELH 1093.5106 y8 
478.2296 b5 1194.5583 y9 
496.1984 y3-H2O 1265.5954 y10 
514.2089 y3     
Table 12. Summary of MS/MS peak information for Hb+APAP adduct. Possible match 
peaks are indicated with an asterisk. 
 
In the BioConfirm data for the α-PVP adduct with Hb, 3 peaks were 
identified in the MS/MS spectrum (Figure 33). Using the potential peak list 
populated by Protein Prospector, 7 additional peaks were identified. The resulting 
10 peaks along with the corresponding fragment can be found in Table 13. 
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Figure 32. MS/MS data for the unmodified peptide containing the Hb β93 cysteine. 
 
Figure 33. MS/MS identification of the adduct formed between α-PVP and Hb β93. (A) 
BioConfirm labeled MS/MS spectrum with 3 peaks identified in the spectrum, all y 
fragments shown in red. (B) Putative structure of α-PVP adduct. (C) Peptide fragmentation 
diagram for MS/MS data. 
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Fragment Mass Fragment 
129.1022 K 
130.0863 y1-NH3 
147.1128 y1 
278.1499 a3 
373.2082 ATLS 
562.2984 LSELH-H2O 
563.3188* a6 
818.4068+2 MH-NH3+2 
826.9201+2 MH+2 
846.4519 y5 
Table 13. Summary of MS/MS peak information for Hb+α-PVP adduct. Possible match 
peaks are indicated with an asterisk. 
 
4.3.4 Task 3 Discussion 
 Task 3 examined the capability of drugs of abuse to form covalent adducts 
with hemoglobin in vitro. As discussed in section 2.4.1, adducts formed between 
drugs of abuse and proteins is not a new concept, but the literature is limited. 
Few examples exist of studies analyzing these adducts, with the exceptions 
being ethanol, morphine, and cocaine.52,53,59,65 Acetaminophen has also been 
shown via HPLC analysis to bind directly to hemoglobin.138 However, there has 
not been any mass spectrometric investigation into these formed adducts. Table 
10 exhibits information supporting the formation of adducts formed between 
hemoglobin and six drugs of interest in this study; APAP, α-PVP, METH, NAL, 
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OXY, and THC. The use of HRMS analysis increased the confidence in these 
data, despite the uncertainty regarding the adducts with Δm/z ≥5 ppm. 
Additionally, the adducts listed as having more than one modification introduce 
another degree of uncertainty, but were still included as the BioConfirm software 
identified them. Each modification for a drug of abuse adduct had to be manually 
generated. An example of a manual modification setup for BioConfirm can be 
seen in Figure 34. 
 
 
Figure 34. Example of custom modification settings used for BioConfirm analysis 
 
 An important note regarding all of the observed adducts is that they are 
drug specific. Rather than a portion of a drug being covalently bound, such as a 
phenyl ring or amine, the entire drug moiety is bound to the cysteine of Hb. This 
implies that any long-term biomarkers arising from the use of protein adducts will 
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be indicative of a specific drug, rather than a class of drugs. It also implies that 
the use of protein adducts as biomarkers could be used in confirmatory tests, 
rather than screening. There may also be more adducts formed than what was 
detected by the QTOF instrument, including those formed with different drugs of 
interest. The formed adducts are often produced at very low concentrations, and 
it is possible that the instrument, based upon user parameters, disregarded 
adduct peaks in favor of fragments with significantly higher concentration. 
 The MS/MS data provide further evidence of the covalent adduction by 
APAP and α-PVP. Both of these drugs were covalently bound to Hb β93, rather 
than the other two possible cysteines. This is unsurprising since Hb β93 is the 
most reactive cysteine residue found in Hb99, as it lies largely exposed on the 
surface of the protein (Figure 35).  
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Figure 35. Space-filled model of Hb with Hb β93 highlighted in green. 
 
Figure 36. Space-filled model of Hb with His and Lys residues highlighted in green. 
MS/MS data were unable to be collected for nine of the eleven adducts 
observed in the MS analysis. This could be the result of low concentrations of the 
formed adducts. As mentioned earlier in this section, the adducts are present in 
much lower concentrations than the other components of the assay analyzed by 
the instrument. Parameters of the QTOF analytical method may have 
accidentally excluded some of the adducts. To be certain, exclusion lists would 
need to be created containing the masses of the non-adducted peptides and any 
other irrelevant molecules. 
While Hb β93 is the most reactive cysteine, it is possible that other adducts 
are formed with additional nucleophilic amino acid residues on the hemoglobin 
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molecule. As visible in Figure 36, there are many other nucleophilic sites in the 
hemoglobin protein. These include the amino acids histidine and lysine, both of 
which have been shown to form covalent adducts with electrophiles.73 Any of 
these adducts would have been missed since cysteine was specifically targeted 
in the BioConfirm parameters allowed for modifications (see Figure 34). Further 
work would therefore be required to determine any additional sites of possible 
adduction by the drugs of interest. 
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5. Summary and Prospect 
 The goal of this research was to investigate the potential of adduct 
formation between selected drugs of abuse and the blood protein hemoglobin. 
This was accomplished through a series of steps, including the determination of 
fragmentation of the parent drugs and the analysis of adduction with the small 
tripeptide glutathione. This work successfully compiled a list of common 
fragments for all 16 of the drugs of interest, which, although not thoroughly 
utilized for this work, may provide insight in the future to potential fragmentation 
by adducted drug moieties. This work also identified and characterized 22 
adducts with GSH, 12 of which were novel. Although structural determination 
was not a focus of this research, plausible structures for 9 of the 12 novel 
adducts were proposed. Positive ionization analysis of the GSH adducts may 
provide more details into the missing structures and aid in confirming the 
proposed structures of the putative adducts. Lastly, this research was able to 
successfully collect HRMS data for eleven Hb adducts with the drugs of interest 
and MS/MS data for two adducts, thus confirming the adduction by α-PVP and 
APAP. 
 This research has laid the groundwork for future expansion into the topic 
of covalent protein adduction by drugs of abuse. One major area of potential 
future work is the investigation of other proteins, specifically human serum 
albumin (HSA). HSA, like Hb, is a common blood protein with a free cysteine 
residue at Cys34. HSA is also produced in the liver, where much of the 
metabolism in the body takes place. This could potentially drive the adduction of 
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short-lived reactive metabolites with HSA. There is also a plethora of literature 
regarding the adduction of compounds to HSA. The metabolically generated 
carcinogen (±)-r-7,t-8-dihydroxy-c-9,c-10-epoxy-7,8,9,10-tetrahydrobenze (anti-
BaPDE) has been shown via fluorescence line narrowing spectroscopy to 
produce multiple adducts with HSA.140 Adducts have also been observed 
between HSA and atrazine, a common herbicide.141 Finally, the structurally 
similar bovine serum albumin (BSA) has been shown to form adducts with 
APAP.123 HSA, much like Hb, is not limited to cysteine as possible sites of 
adduction, as studies have shown the nucleophilic properties of multiple histidine 
and lysine residues promote adduction.73 
 The concentration of many protein adducts has been shown to be very 
low, with in vitro studies reporting that a majority of analyzed compounds 
exhibited protein binding with less than 10% of the overall metabolome.142  
APAP, a drug observed in the present study to have the highest adduct 
concentrations, was observed modifying proteins with 3.1% of the overall 
metabolome.142 In vivo studies have shown even lower concentrations present, 
with Rubino et al. reporting that hemoglobin modified by a mass 200 Daltons or 
higher was present at concentrations of 1ppb or lower.143 A solution to this 
limitation would be to carry out an enrichment procedure by isolating the modified 
protein before analysis.  
 This work has many implications in the field of forensics. At the present 
time, hair analysis is the only available method for long-term detection of illicit 
drug use.  However, hair analysis suffers from methodological and interpretive 
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challenges, and the mechanisms by which most drugs incorporate into hair are 
not clearly established.21 Additionally, current blood and urine biomarkers are 
removed from the body after just a few days, restricting the window of detection 
for many drugs of abuse. The use of protein adducts as long-term biomarkers of 
exposure may be used to supplement existing analytical methods to ensure 
complete detection of drugs of abuse. As all of the thusly identified proteins 
adducts are specific to individual drugs, it may be possible to confirm not only the 
class of drugs consumed but also the exact drug consumed based upon the 
MS/MS data collected for an individual’s sample. This specificity combined with 
the overall stability makes long-term biomarkers of exposure a favorable and 
effective application of protein adducts formed by drugs of abuse. 
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APPENDIX 
Appendix 1.  Precursor ion scan TIC and XIC data for the drugs of abuse. 
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